

**A PHASE 4, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY,  
PLACEBO-AND ACTIVE-CONTROLLED, SINGLE-DOSE, SIX-WAY  
CROSSOVER STUDY EVALUATING THE ABUSE POTENTIAL OF LYRICA®  
TAKEN ORALLY CONCOMITANTLY WITH OXYCODONE HYDROCHLORIDE  
IN HEALTHY NON-DRUG DEPENDENT, RECREATIONAL OPIOID USERS**

**Investigational Product Number:** PD-144723  
**Investigational Product Name:** Lyrica® (pregabalin)  
**United States (US) Investigational New Drug (IND) Number:** 053763  
**European Clinical Trials Database (EudraCT) Number:** Not Applicable (N/A)  
**Protocol Number:** A0081365  
**Phase:** 4

**Short Title:** Evaluating the Abuse Potential of Lyrica When Taken Orally Concomitantly with Oxycodone Hydrochloride in Healthy Non-drug Dependent, Recreational Opioid Users

<b>Sponsor:</b>	Upjohn US 1 LLC 235 East 42nd Street New York, NY 10017-5703	
<b>Sponsor Contacts:</b>	<div>██████████ Clinical Sciences ██████████ ██████████ ██████████ ██████████ ██████████</div>	<div>██████████ Global Clinical Operations ██████████ ██████████ ██████████ ██████████</div>

This document and accompanying materials contain confidential information belonging to Upjohn. Except as otherwise agreed to in writing, by accepting or reviewing these documents, you agree to hold this information in confidence and not copy or disclose it to others (except where required by applicable law) or use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, Upjohn must be promptly notified.

### PROTOCOL APPROVAL – SPONSOR SIGNATORY

<b>Study Title</b>	A phase 4, randomized, double-blind, double-dummy, placebo-and active-controlled, single-dose, six-way crossover study evaluating the abuse potential of Lyrica® taken orally concomitantly with Oxycodone hydrochloride In healthy non-drug dependent, recreational opioid users
<b>Protocol Number</b>	A0081365
<b>Amendment No.</b>	3.0
<b>Protocol Date</b>	17 Nov 2021

Protocol accepted and approved by:

[REDACTED]

Global Clinical Operations [REDACTED]

[REDACTED]

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Date

[REDACTED]

Clinical Sciences [REDACTED]

[REDACTED]

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Date

## Protocol Amendment Summary of Changes Table

Document History		
Document	Version Date	Summary of Changes and Rationale
Amendment 3	17 November 2021	<ul style="list-style-type: none"> <li>Administrative changes to update Sponsor contact details and authorized sponsor protocol approver</li> <li>Changes to allow more forms of female contraception</li> </ul> <p>Complete summary of changes is provided in Appendix 10.12</p>
Amendment 2	23 December 2020	<ul style="list-style-type: none"> <li>The sponsor for this study is changed from 'Pfizer' to 'Upjohn US 1 LLC'</li> <li>Administrative and typographic changes for harmonization within the protocol were implemented.</li> </ul> <p>Complete summary of changes is provided in Appendix 10.12</p>
Amendment 1	12 November 2020	<p>Updated sample size of Enrolled and Completer populations in section 1.2, section 4.1 and section 9.2.</p> <p>Added The Modified Completer Population criteria in Section 9.3.</p> <p>The Modified Completer Population will include all randomized participants in the Completer Population, however will exclude any participant who meets either or both of the following criteria for Drug Liking VAS:</p> <ol style="list-style-type: none"> <li><math>E_{\max}</math> scores are within a 5 point difference across all 6 treatments (ie, Maximum <math>E_{\max}</math> score – Minimum <math>E_{\max}</math> score <math>\leq 5</math>).</li> <li><math>E_{\max}(P) &gt; 60</math> and <math>E_{\max}(P) - E_{\max}(\text{Oxy20}) \geq 5</math>.</li> </ol> <p>Where <math>E_{\max}(P)</math> and <math>E_{\max}(\text{Oxy20})</math> are the VAS <math>E_{\max}</math> scores for placebo and oxycodone HCl IR 20 mg, respectively.</p>
Original Protocol	13 October 2020	Not applicable (N/A)

## TABLE OF CONTENTS

LIST OF TABLES.....	9
LIST OF FIGURES .....	9
1. PROTOCOL SUMMARY.....	10
1.1. Synopsis (Not Applicable).....	10
1.2. Schema.....	10
1.3. Schedule of Activities (SoA) .....	11
2. INTRODUCTION .....	16
2.1. Study Rationale.....	16
2.2. Background .....	17
2.2.1. Clinical Overview .....	17
2.3. Benefit/Risk Assessment .....	18
3. OBJECTIVES AND ENDPOINTS.....	19
4. STUDY DESIGN .....	20
4.1. Overall Design.....	20
4.1.1. Screening.....	21
4.1.2. Qualification Phase (Visit 2; Days 0 to 3).....	21
4.1.2.1. Naloxone Challenge (Day 0) .....	21
4.1.2.2. Instrument Training.....	22
4.1.2.3. Drug Discrimination (Days 1 to 3).....	22
4.1.3. Treatment Phase (Visits 3 to 8).....	23
4.2. Scientific Rationale for Study Design.....	23
4.3. Justification for Dose.....	24
4.4. End of Study Definition.....	25
5. STUDY POPULATION.....	25
5.1. Inclusion Criteria .....	25
5.2. Exclusion Criteria .....	26
5.3. Lifestyle Considerations .....	29
5.3.1. Meals and Dietary Restrictions .....	29
5.3.2. Caffeine, Alcohol, and Tobacco.....	29
5.3.3. Activity.....	30
5.3.4. Contraception.....	30

5.4. Screen Failures.....	30
6. STUDY INTERVENTION .....	30
6.1. Study Interventions Administered.....	30
6.1.1. Administration .....	31
6.2. Preparation/Handling/Storage/Accountability.....	31
6.2.1. Preparation and Dispensing.....	32
6.3. Measures to Minimize Bias: Randomization and Blinding .....	32
6.3.1. Allocation to Investigational Product .....	32
6.3.2. Breaking the Blind .....	33
6.4. Study Intervention Compliance.....	33
6.5. Concomitant Therapy .....	33
6.6. Dose Modification.....	34
6.7. Emergency Intervention .....	34
6.8. Intervention After the End of the Study .....	34
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL.....	34
7.1. Discontinuation of Study Intervention.....	34
7.2. Participant Discontinuation/Withdrawal from the Study .....	36
7.3. Lost to Follow up .....	37
8. STUDY ASSESSMENTS AND PROCEDURES.....	37
8.1. Efficacy Assessments .....	39
8.2. Safety Assessments .....	39
8.2.1. Physical Examinations.....	39
8.2.2. Vital Signs .....	39
8.2.2.1. Respiratory Monitoring.....	40
8.2.2.2. Temperature.....	40
8.2.3. Pupillometry .....	40
8.2.4. Electrocardiograms.....	41
8.2.4.1. Continuous Cardiac Monitoring by Telemetry.....	41
8.2.5. Clinical Safety Laboratory Assessments.....	42
8.2.6. Suicidal Ideation and Behavior Risk Monitoring.....	42
8.2.6.1. Columbia Suicidality Severity Rating Scale (C-SSRS) .....	42

8.2.6.2. Risk Assessment During Screening.....	42
8.2.6.3. Risk Assessment During the Study .....	43
8.2.7. Pregnancy Testing.....	43
8.3. Adverse Events and Serious Adverse Events .....	44
8.3.1. Time Period and Frequency for Collecting AE and SAE Information .....	44
8.3.1.1. Reporting SAEs to Pfizer Safety.....	45
8.3.1.2. Recording Non-serious AEs and SAEs on the CRF .....	45
8.3.2. Method of Detecting AEs and SAEs.....	45
8.3.3. Follow-up of AEs and SAEs .....	45
8.3.4. Regulatory Reporting Requirements for SAEs.....	45
8.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational Exposure.....	46
8.3.5.1. Exposure During Pregnancy .....	46
8.3.5.2. Exposure During Breastfeeding .....	46
8.3.5.3. Occupational Exposure.....	46
8.3.6. Medication Errors.....	47
8.4. Treatment of Overdose .....	47
8.5. Pharmacokinetics .....	48
8.6. Pharmacodynamics .....	49
8.6.1. Subjective Effects.....	49
8.6.1.1. Visual Analog Scale (VAS) .....	49
8.7. Genetics.....	50
8.7.1. Specified Genetics.....	50
8.7.2. Banked Biospecimens for Genetics .....	50
8.8. Biomarkers .....	50
8.9. Health Economics .....	50
9. STATISTICAL CONSIDERATIONS .....	50
9.1. Statistical Hypothesis.....	51
9.2. Sample Size Determination.....	51
9.3. Populations for Analysis.....	52
9.4. Statistical Analysis.....	53
9.4.1. Endpoint Analysis.....	53

9.4.2. Study Validity of Analysis of Endpoints.....	54
9.4.3. Analysis of Primary and Secondary Endpoints.....	54
9.4.3.1. Pharmacodynamic Analysis.....	55
9.4.3.2. Pharmacokinetic Analysis .....	57
9.4.4. Efficacy Analyses.....	58
9.4.5. Safety Analyses.....	58
9.4.5.1. Electrocardiogram Analyses .....	58
9.4.6. Exploratory Analyses .....	59
9.5. Interim Analyses.....	59
9.6. Data Monitoring Committee .....	59
10. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS .....	60
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations.....	60
10.1.1. Regulatory and Ethical Considerations .....	60
10.1.1.1. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP.....	60
10.1.2. Financial Disclosure .....	61
10.1.3. Informed Consent Process.....	61
10.1.4. Data Protection.....	62
10.1.5. Dissemination of Clinical Study Data.....	62
10.1.6. Data Quality Assurance .....	63
10.1.7. Source Documents.....	64
10.1.8. Study and Site Closure.....	65
10.1.9. Publication Policy.....	65
10.1.10. Sponsor’s Qualified Medical Personnel.....	66
10.2. Appendix 2: Clinical Laboratory Tests.....	67
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting.....	69
10.3.1. Definition of AE.....	69
10.3.2. Definition of SAE.....	70
10.3.3. Recording/Reporting and Follow-up of AEs and/or SAEs .....	71
10.3.4. Reporting of SAEs.....	74

10.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information.....	75
10.4.1. Male Participant Reproductive Inclusion Criteria.....	75
10.4.2. Female Participant Reproductive Inclusion Criteria .....	75
10.4.3. Woman of Childbearing Potential (WOCBP).....	76
10.4.4. Contraception Methods.....	76
10.5. Appendix 5: Genetics.....	79
10.6. Appendix 6: Liver Safety: Suggested Actions and Follow-up Assessments.....	80
10.7. Appendix 7: ECG Findings of Potential Clinical Concern .....	82
10.8. Appendix 8: Clinical Opiate Withdrawal Scale.....	84
10.9. Appendix 9: VAS Assessment Methods.....	86
10.10. Appendix 10: Alternative Measures During Public Emergencies .....	89
10.10.1. Eligibility .....	89
10.10.2. Telehealth Visits.....	89
10.10.3. Alternative Facilities for Safety Assessments.....	89
10.10.4. Study Intervention .....	89
10.10.5. Home Health Visits .....	89
10.10.6. Adverse Events and Serious Adverse Events .....	89
10.10.7. Efficacy Assessments .....	89
10.10.8. Independent Oversight Committees.....	89
10.11. Appendix 11: Abbreviations .....	90
10.12. Appendix 12: Summary of Changes .....	94
11. REFERENCES .....	100



## LIST OF TABLES

Table 1.	Schedule of Activities for Screening, Naloxone Challenge and Qualification Phase.....	11
Table 2.	Schedule of Activities for the Treatment Phase.....	14
Table 3.	Schema for Qualification Phase.....	22
Table 4.	Derivation of Pharmacodynamic Parameters.....	56
Table 5.	Pharmacokinetic Parameters .....	57
Table 6.	Laboratory Tests.....	67
Table 7.	Other Subjective Effects Visual Analog Scales .....	88
Table 8.	Summary of changes from Amendment 1.0 dated 12 Nov 2020 to Amendment 2.0 dated 24 Dec 2020 .....	95
Table 9.	Summary of changes from Amendment 2.0 dated 24 Dec 2020 to Amendment 3.0 dated 17 Nov 2021 .....	98

## LIST OF FIGURES

Figure 1.	Study Schema.....	10
Figure 2.	Screen Display of Drug Liking VAS .....	86
Figure 3.	Screen Display of High VAS .....	87
Figure 4.	Screen Display of Overall Drug Liking VAS.....	87
Figure 5.	Screen Display of Take Drug Again VAS.....	88


## 1. PROTOCOL SUMMARY

### 1.1. Synopsis (Not Applicable)

### 1.2. Schema

The participants will be screened, undergo a naloxone challenge to ensure that they are not drug dependent and a drug discrimination test to demonstrate that they can differentiate between a positive control and placebo. Once the participant has passed these tests, they may be enrolled into the Treatment Phase of the study. The Treatment Phase of the study will use a Williams square study design involving approximately 60 adult male and female (at least 20% females) participants (10 participants in each sequence) to ensure 48 participants complete the Treatment Phase of the study, as shown in Figure 1. Drop out participants for non-safety reasons in the treatment phase can be replaced at the discretion of the Investigator in consultation with the Sponsor.

**Figure 1. Study Schema**



### 1.3. Schedule of Activities (SoA)

The SoA (Table 1 and Table 2) provide an overview of the protocol visits and procedures. Refer to the STUDY ASSESSMENTS AND PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the protocol. The investigator may schedule visits (unplanned visits) in addition to those listed in the SoA table, to conduct evaluations or assessments required to protect the well-being of the participant.

**Table 1. Schedule of Activities for Screening, Naloxone Challenge and Qualification Phase**

Visit Identifier	Visit 1 Screening	Visit 2 (Qualification Phase)														
		Naloxone Challenge	Drug Discrimination													
Study Day	Within 28 Days prior to Visit 2 (Day -28 to Day -1)	Day 0	Days 1 and 2													Day 3 <sup>P</sup>
Hours Post Dose			Pre-dose	0	0.25	0.5	1	1.5	2	2.5	3	3.5	4	5	24	
Clinical Research Unit (CRU) admission		X <sup>a</sup>	→	→	→	→	→	→	→	→	→	→	→	→		
Informed consent	X <sup>o</sup>															
Inclusion/Exclusion	X															
Demographics	X															
Medical history (including drug abuse)	X	X														
Ongoing eligibility review		X													X	
Prior/Concomitant medication (including past year recreational drug history)	X	→	→	→	→	→	→	→	→	→	→	→	→	→	→	
Physical examination <sup>b</sup>	X	X													X	
Safety laboratory tests	X	X														
HIV, HBsAg, HBcAb, HCVab, HAV IgM, HAV IgG	X															
Urine drug testing	X	X														
Serum Pregnancy test (WOCBP only)	X <sup>c</sup>															
Follicular stimulating hormone (FSH)	X <sup>d</sup>															

Visit Identifier	Visit 1 Screening	Visit 2 (Qualification Phase)													
		Naloxone Challenge	Drug Discrimination												
Study Day	Within 28 Days prior to Visit 2 (Day -28 to Day -1)	Day 0	Days 1 and 2												Day 3 <sup>p</sup>
Urine Pregnancy test (WOCBP only)		X <sup>e</sup>													
Contraception check	X														
Alcohol breathalyzer or urine	X	X													
Vital signs <sup>f</sup>	X	X <sup>g</sup>	X		X	X	X	X	X	X	X	X	X	X	X
Pulse oximetry, SpO <sub>2</sub>			X		X	X	X	X	X	X	X	X	X	X	
Respiratory rate			X		X	X	X	X	X	X	X	X	X	X	
12-lead Electrocardiogram <sup>h</sup>	X	X													
Randomization for Qualification Phase, Day 1			X <sup>r</sup>												
Pharmacodynamic instrument training <sup>q</sup>		X													
Cardiac telemetry <sup>i</sup>			X	→	→	→	→	→	→	→	→	→	→	→	
Pupillometry			X		X	X	X	X	X	X	X	X	X	X	
Study treatment administered		X <sup>j</sup>		X											
Visual Analogue Scales (VAS) <sup>k</sup>			X <sup>k(a)</sup>		X	X	X	X	X	X	X	X	X	X	
Take Drug Again VAS, Overall DrugLiking VAS														X	
Clinical Opiate Withdrawal Scale (COWS)		X <sup>l</sup>													
Adverse and serious adverse events <sup>m</sup>	X	X	→	→	→	→	→	→	→	→	→	→	→	→	X
Columbia Suicide-Severity Rating Scale	X	X													X
Evaluate to proceed <sup>n</sup>		X													X
Discharge from CRU															X

Abbreviations: COWS = Clinical Opiate Withdrawal Scale; CRU = Clinical Research Unit; FSH = follicle stimulating hormone; HAV IgG = hepatitis A virus immunoglobulin G; HAV IgM = hepatitis A virus immunoglobulin M; HBsAg = hepatitis B surface antigen; HCVab = hepatitis C antibody; HIV = human immunodeficiency virus; SpO<sub>2</sub> = saturated oxygen; VAS = Visual Analogue Scale; WOCBP = women of childbearing potential.

- a. Admission should occur in the morning to ensure adequate time for pre-dose review of clinical laboratory results.
- b. Full physical examination (PE) (including height and weight) only needs to be done once, ie, at Screening or at Day 0 of Visit 2. However, height and weight must be performed at Screening to obtain BMI for determination of eligibility. A brief symptom-directed physical examination will be conducted as needed on Day 0 and prior to discharge on Day 3.
- c. Review of results are required prior to dosing on Visit 2 (ie, Naloxone Challenge).
- d. For confirmation of postmenopausal status only.
- e. Must be reviewed and confirmed as negative prior to dosing on Day 0.
- f. Includes pulse rate, systolic and diastolic blood pressures. Temperature will be measured at Screening and upon admission on Day 0 of the Naloxone Challenge Phase. Vital signs are measured after a resting period of at least 5 minutes in a sitting position.
- g. Vital signs will be recorded at pre-dose (first naloxone dose) and at 5 minutes, 0.25, 0.5, 1, 1.5, and 2 hours following the second dose of naloxone.
- h. Conducted after a resting period of at least 10 minutes in a supine position.
- i. Continuous cardiac telemetry (heart rate, cardiac rhythm, and oxygen saturation) will be monitored for approximately 5 hours post-dose or longer at the discretion of the clinical research unit.
- j. Naloxone (0.2 mg IV) is administered first. If there are no signs of withdrawal apparent within 30 seconds after administration, another 0.6 mg naloxone IV is administered.
- k. Include VASs for Drug Liking, High, Sleepy, Dizzy, Nausea, and Feel Sick;  
k(a) Only VASs for High, Sleepy, Dizzy, Nausea, and Feel Sick are administered at pre-dose.
- l. COWS is collected and recorded at pre-dose, and at 30 seconds following the first naloxone dose and 5 minutes after the second dose is administered.
- m. Assessed throughout and collected using open-ended questions. Symptoms of withdrawal following naloxone administration (Naloxone Challenge Phase) will not be collected as adverse events unless they meet the criteria for an SAE. Serious AEs will be collected from the time the informed consent is signed through and including 28 calendar days after the last administration of the investigational product. During the Drug Discrimination Phase, AEs are collected at pre-dose and 0.25, 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5 and 24 hours post-dose.
- n. Evaluation to proceed must occur prior to next scheduled time and event.
- o. Assign a single participant identifier number.
- p. If participants fail to qualify, all AEs will be reported with no further SoA testing.
- q. Retraining is allowed, as needed.
- r. Randomization can be done on Day 0, as needed, following completion of naloxone challenge test.

**Table 2. Schedule of Activities for the Treatment Phase**

Study Day	Visits 3 to 8 Treatment Phase Periods 1 to 6 <sup>a</sup>																		Follow-up	Early termination/ discontinuation (DC)
	Baseline Day -1	Day 1														Day 2		Day 3	28-35 Days <sup>n</sup>	
Hours Post Dose		Pre- dose	0	0.25	0.5	1	1.5	2	2.5	3	3.5	4	6	8	12	24	36	48		
CRU admission	X	→	→	→	→	→	→	→	→	→	→	→	→	→	→	→	→	→		
Medical history update	X																		X	
Continuing eligibility check <sup>b</sup>	X																			
Concomitant medication	X	X	→	→	→	→	→	→	→	→	→	→	→	→	→	→	→	→	X	X
Physical examination <sup>c</sup>	X																	X <sup>m</sup>		X
Safety laboratory tests <sup>d</sup>																		X <sup>m</sup>		X
Suicidality assessment	X																		X	X
Urine drug testing <sup>e</sup>	X																			
Serum pregnancy test (WOCBP only)																		X <sup>m</sup>		X
Urine pregnancy test (WOCBP only) <sup>f</sup>	X																			
Contraception check	X																		X	X
Alcohol breathalyzer or urine	X																			
Vital signs <sup>g</sup>	X	X		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X		X
Pulse oximetry, SpO <sub>2</sub>		X	→	→	→	→	→	→	→	→	→	→	→	X	X	X				X
Respiratory rate		X	→	→	→	→	→	→	→	→	→	→	→	X	X	X				
Tidal volume		X	→	→	→	→	→	→	→	→	→	→	→	X	X	X				
End-tidal carbon dioxide		X	→	→	→	→	→	→	→	→	→	→	→	X	X	X				
12-lead Electrocardiogram <sup>o</sup>	X																	X		X
Randomization		X <sup>h</sup>																		
Pharmacodynamic (instrument) training/practice session	X																			
Cardiac telemetry <sup>i</sup>		X	→	→	→	→	→	→	→	→	→	→	→	→						
Pupillometry		X		X		X	X	X	X	X	X	X	X	X	X	X	X	X		
Study treatment administration			X																	
VAS <sup>j</sup>		X <sup>j(a)</sup>		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X		
VAS for Good Drug Effect, Bad Drug Effect, and Any Drug Effect				X	X	X	X	X	X	X	X	X	X	X	X	X	X	X		
“Overall Drug Liking” and “Take Drug Again” VAS																X	X	X		
Upjohn Prep D1 Banked biospecimen <sup>k</sup>	X																			
Pharmacokinetic blood sampling		X		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X		X

Study Day	Visits 3 to 8 Treatment Phase Periods 1 to 6 <sup>a</sup>																	Follow-up	Early termination/ discontinuation (DC)	
	Baseline Day -1	Day 1														Day 2		Day 3	28-35 Days <sup>n</sup>	
Hours Post Dose		Pre- dose	0	0.25	0.5	1	1.5	2	2.5	3	3.5	4	6	8	12	24	36	48		
Adverse and serious event monitoring <sup>l</sup>	X	X	→	→	→	→	→	→	→	→	→	→	→	→	→	→	→	→	X	X
Columbia Suicide-Severity Rating Scale	X	X																X	X	X
Discharge from CRU																		X		
Discharge from Study																			X	

Abbreviations: CRU = Clinical Research Unit; SpO2 = saturated oxygen; UDS = urine drug screening; VAS = Visual Analogue Scale; WOCBP = women of childbearing potential.

- Treatment Periods will be separated by a minimum of 4 days (not to exceed 28 days) between dosing.
- Continuing eligibility checks will include checks of urine drug screening (UDS), ethanol breath test, pregnancy tests, compliance with Lifestyle guidelines, and any changes to medical conditions that may require participant rescheduling or discontinuation.
- Physical examinations will be brief and symptom-directed (if a change in medical history is reported). Symptom-directed physical examinations may be performed at admission to each visit at the discretion of the Investigator. A complete physical examination will be conducted at End of Study (EoS) or early termination (ET).
- See [Appendix 2](#).
- Urine drug screens may be repeated for confirmatory purposes, at the discretion of the Investigator or designee.
- For all female participants, urine pregnancy tests will be obtained upon admission to each Treatment Visit and a serum pregnancy test will be obtained at the End of Study Visit.
- Vital signs (including pulse rate, systolic and diastolic blood pressures) are measured at the nominal time points ( $\pm 10$  minutes) after a resting period of at least 5 minutes in a sitting position. Temperature will be measured on Day -1 of each Treatment Visit only.
- Pre-dose or Day -1 for Visit 3 only.
- Continuous cardiac telemetry (heart rate, cardiac rhythm, and oxygen saturation) will be monitored from predose to approximately 8 hours post-dose or longer at the discretion of the clinical research unit.
- Include VASs for Drug Liking, High, Sleepy, Dizzy, Nausea, and Feel Sick measured at the nominal time points ( $\pm 5$  minutes);  
j (a) Only VASs for High, Sleepy, Dizzy, Nausea, and Feel Sick are administered at pre-dose.
- Visit 3 pre-dose only on Day -1. If not collected on the designated collection day, collect at the next available time point when biospecimens are being collected in conjunction with a participant visit.
- Spontaneous AE reporting will occur throughout study; however, AEs will also be elicited using non-leading questions during the Treatment Phase at pre-dose and at 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36 and 48 hours post dosing. Serious AEs will be collected from the time the informed consent is signed through and including 35 calendar days after the last administration of the investigational product.
- End of the study only.
- Contact may occur via telephone contact and must occur 28 to 35 days from administration of the final dose of investigational product.
- Conducted after a resting period of at least 10 minutes in a supine position.

## 2. INTRODUCTION

### 2.1. Study Rationale

LYRICA® (pregabalin) immediate release (IR) is indicated for neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, neuropathic pain associated with spinal cord injury and adjunctive therapy for the treatment of partial onset seizures in patients 1 month of age and older.

Pregabalin is an analogue of the neurotransmitter gamma-amino butyric acid (GABA). Its mechanism of action has not been established, but it has a similar pharmacological profile to that of gabapentin. Despite being a derivative of GABA, it is not active at GABA receptors and does not appear to mimic GABA physiologically. Pregabalin is not known to be active at receptor sites associated with drugs of abuse; however, several animal models of anxiolytic activity have demonstrated that pregabalin may have antianxiety effects similar to classic benzodiazepines. Pregabalin is not known to be active at receptor sites associated with drugs of abuse; however, pregabalin is associated with central nervous system (CNS) adverse effects such as somnolence and confusion,<sup>1</sup> and might cause decreased respiratory rate and the combined use of pregabalin and opioids may increase overdose risk.<sup>2</sup> The abuse potential of pregabalin has been shown to be particularly high among opioid addicts and other substance-dependent patients.<sup>3,4</sup>

In a study of recreational users (N=15) of sedative/hypnotic drugs (Protocol Clinical Study Report [CSR] 720-30015, 1008-098: Abuse Liability of Pregabalin (CI-1008) in Recreational Sedative/Alcohol Users), including alcohol, pregabalin (450 mg, single dose) received subjective ratings of "good drug effect," "high" and "liking" to a degree that was similar to diazepam (30 mg, single dose).<sup>5</sup> In controlled clinical studies in over 5500 patients, 4% of pregabalin treated patients and 1% of placebo treated patients overall reported euphoria as an adverse reaction, though in some patient populations studied, this reporting rate was higher and ranged from 1% to 12%.<sup>6</sup>

Pregabalin is a Schedule V controlled substance. Since Lyrica® was approved on 30 December, 2004, the epidemiological studies showed that pregabalin may be used in conjunction with opioids to enhance the 'high' obtained from opioids.<sup>7-9</sup> In addition, observational studies have suggested pregabalin is associated with drug overdose death among individuals with concomitant opioid use.<sup>3,10</sup> A clinical trial (rather than a nonclinical or observational study) is required to evaluate the abuse potential of pregabalin. As a consequence, the FDA requires this post-authorization safety study (PASS) to evaluate pregabalin in a cross-over design with comparison to placebo and a positive control, oxycodone hydrochloride (HCl), regarding abuse-related subjective responses, physiological responses (including an assessment of respiratory depression), and drug pharmacokinetics (PK) in a healthy non-drug dependent population with drug abuse experience.



## 2.2. Background

Pregabalin binds with high affinity to the alpha-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. Although the mechanism of action of pregabalin has not been fully elucidated, results with genetically modified mice and with compounds structurally related to pregabalin (such as gabapentin) suggest that binding to the alpha-delta subunit may be involved in pregabalin's anti-nociceptive and antiseizure effects in animals. In animal models of nerve damage, pregabalin has been shown to reduce calcium dependent release of pro-nociceptive neurotransmitters in the spinal cord, possibly by disrupting alpha -delta containing-calcium channel trafficking and/or reducing calcium currents. Evidence from other animal models of nerve damage and persistent pain suggest the anti-nociceptive activities of pregabalin may also be mediated through interactions with descending noradrenergic and serotonergic pathways originating from the brainstem that modulate pain transmission in the spinal cord.

While pregabalin is a structural derivative of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), it does not bind directly to GABA, or benzodiazepine receptors, does not augment GABA responses in cultured neurons, does not alter rat brain GABA concentration or have acute effects on GABA uptake or degradation. However, in cultured neurons prolonged application of pregabalin increases the density of GABA transporter protein and increases the rate of functional GABA transport. Pregabalin does not block sodium channels, is not active at opiate receptors, and does not alter cyclooxygenase enzyme activity. It is inactive at serotonin and dopamine receptors and does not inhibit dopamine, serotonin, or noradrenaline reuptake.

### 2.2.1. Clinical Overview

Lyrica® formulations are available in capsule strengths of 25 mg, 50 mg, 75 mg, 100 mg, 200 mg, 225 mg and 300 mg and in a 20 mg/mL solution. Following oral administration under fasting conditions, pregabalin reaches peak plasma concentrations within 1.5 hours. Pregabalin oral bioavailability is greater than or equal to 90% and is independent of dose. Following single- (25 to 300 mg) and multiple-dose (75 to 900 mg/day) administration, maximum plasma concentrations ( $C_{max}$ ) and area under the plasma concentration-time curve (AUC) values increased linearly. Following repeated administration, steady state was achieved within 24 to 48 hours. Multiple-dose PK can be predicted from single-dose data.<sup>6</sup>

The rate of pregabalin absorption is decreased when given with food, resulting in a decrease in  $C_{max}$  of approximately 25% to 30% and an increase in time for peak concentration ( $T_{max}$ ) to approximately 3 hours. However, administration of pregabalin with food has no clinically relevant effect on the total absorption of pregabalin.<sup>11</sup>

Pregabalin does not bind to plasma proteins. The apparent volume of distribution of pregabalin following oral administration is approximately 0.5 L/kg. Pregabalin is a substrate for system L transporter which is responsible for the transport of large amino acids across the blood brain barrier. Although there are no data in humans, pregabalin has been shown to cross the blood brain barrier in mice, rats, and monkeys. In addition, pregabalin has been shown to cross the placenta in rats and is present in the milk of lactating rats.

Pregabalin undergoes negligible metabolism in humans. Following a dose of radiolabeled pregabalin, approximately 90% of the administered dose was recovered in the urine as unchanged pregabalin. The N-methylated derivative of pregabalin, the major metabolite of pregabalin found in urine, accounted for 0.9% of the dose. In preclinical studies, pregabalin (S-enantiomer) did not undergo racemization to the R-enantiomer in mice, rats, rabbits, or monkeys. Pregabalin is eliminated from the systemic circulation primarily by renal excretion as unchanged drug with a mean elimination half-life of 6.3 hours in participants with normal renal function. Mean renal clearance was estimated to be 67.0 to 80.9 mL/min in young healthy participants. Because pregabalin is not bound to plasma proteins this clearance rate indicates that renal tubular reabsorption is involved. Pregabalin elimination is nearly proportional to creatinine clearance ( $CL_{cr}$ ).<sup>6</sup>

The immediate-release (IR) oral formulation of oxycodone HCl is indicated for the management of moderate to severe pain where the use of an opioid analgesic is appropriate. Oxycodone is a  $\mu$ -agonist opioid of the morphine type and a Schedule II drug. Like other opioids used for analgesia, it can be abused and is subject to criminal diversion. About 60% to 87% of an oral dose of oxycodone HCl reaches the systemic circulation. Oxycodone dose proportionality has been established. A 30 mg oral dose of oxycodone reaches  $T_{max}$  in  $2.6 \pm 3$  hours and has a half-life ( $t_{1/2}$ ) of  $3.85 \pm 1.3$  hours. A single 10 mg dose of oxycodone oral solution under fasted condition reaches  $T_{max}$  in  $1.25 \pm 0.5$  hours.<sup>12</sup> Oxycodone is extensively metabolized in the liver via cytochrome P3A4/5 (CYP3A4/5) to noroxycodone (45%) and via CYP2D6 to oxymorphone (19%). Both noroxycodone and oxymorphone are further metabolized to noroxymorphone. Noroxycodone exhibits only weak antinociceptive potency; its affinity for  $\mu$ -opioid receptors and potency are much lower than that of oxycodone. Although oxymorphone and noroxymorphone have higher affinity for  $\mu$ -opioid receptors and are more potent compared with oxycodone, neither of them can readily cross the blood–brain barrier (BBB) and, thus their contributions to analgesia effect following oxycodone administration is thought to be clinically insignificant. The elimination half-life of oxycodone has been reported to be approximately 3-5 hours. Due to CYP-mediated metabolism, oxycodone is prone to drug interactions such as concomitant administration with either CYP3A inhibitors/inducers or CYP2D6 inhibitors or both. Oxycodone, as well as other opioid analgesics, may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression. Oxycodone produces respiratory depression by direct action on brain stem respiratory centers. The respiratory depression involves both a reduction in the responsiveness of the brain stem respiratory centers to increases in carbon dioxide tension and to electrical stimulation.<sup>12,13</sup>

Multiple-dose administration of pregabalin (300 mg twice a day) in healthy participants had no effect on the rate and extent of oxycodone single-dose PK. Single-dose administration of oxycodone (10 mg) had no effect on the steady-state PK of pregabalin. However, the impairment of cognitive and gross motor function produced by pregabalin alone was minimally increased when pregabalin and oxycodone were given in combination.<sup>14</sup>

### 2.3. Benefit/Risk Assessment

Lyrica® and oxycodone HCl are not expected to provide any clinical benefit to healthy participants in this study. This study is designed to evaluate the abuse potential of Lyrica®

when taken orally alone and concomitantly with oxycodone HCl in healthy non-dependent, recreational opioid users under a fasted condition.

More detailed information about the known and expected benefits and risks and expected adverse events (AEs) of Lyrica® and oxycodone HCl may be found in the package inserts, which are the single reference safety documents (SRSD) for this study. The SRSD for the pregabalin and oxycodone is their respective United States Prescribing Information (USPI).<sup>6,12</sup>

### 3. OBJECTIVES AND ENDPOINTS

Objectives	Endpoints
<b>Primary:</b>	<b>Primary:</b>
<ul style="list-style-type: none"> <li>To determine the abuse potential of orally administered pregabalin taken concomitantly with oxycodone HCl in non-dependent, recreational opioid users under a fasted condition.</li> </ul>	<ul style="list-style-type: none"> <li>Bipolar visual analogue scale (VAS) for “Drug Liking” [maximum effect (<math>E_{max}</math>)].</li> </ul>
<b>Secondary:</b>	<b>Secondary:</b>
<ul style="list-style-type: none"> <li>To evaluate additional pharmacodynamic (PD) effect and PK of pregabalin and oxycodone HCl taken alone and concomitantly in non-dependent, recreational opioid users under a fasted condition.</li> <li>To evaluate safety of pregabalin and oxycodone HCl taken alone and concomitantly in non-dependent, recreational opioid users under a fasted condition.</li> </ul>	<p><b>Pharmacodynamic Endpoints:</b></p> <ul style="list-style-type: none"> <li>Bipolar VAS for “Drug Liking” [time for <math>E_{max}</math> (<math>TE_{max}</math>), area under the effect-time profile from time zero to the last quantifiable effect (<math>AUEC_{last}</math>), and partial AUEC (<math>AUEC_1</math>, <math>AUEC_2</math>, <math>AUEC_3</math>, <math>AUEC_4</math>, <math>AUEC_8</math>)].</li> <li>Unipolar VAS for “High” [<math>E_{max}</math>, <math>TE_{max}</math>, <math>AUEC_{last}</math>, and partial AUEC (<math>AUEC_1</math>, <math>AUEC_2</math>, <math>AUEC_3</math>, <math>AUEC_4</math>, <math>AUEC_8</math>)].</li> <li>Bipolar VAS for “Take Drug Again” at 24, 36, 48 hour postdose.</li> <li>Bipolar VAS for “Overall Drug Liking” at 24, 36 and 48 hours postdose.</li> <li>Unipolar VAS for “Good Drug Effect”.</li> <li>Unipolar VAS for “Bad Drug Effect”.</li> <li>Unipolar VAS for “Any Drug Effect”.</li> <li>Pupil size (diameter).</li> </ul> <p><b>Pharmacokinetic Endpoints:</b></p> <ul style="list-style-type: none"> <li><math>C_{max}</math>, <math>T_{max}</math>, and area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration (<math>AUC_{last}</math>) of pregabalin and oxycodone.</li> <li>Area under the plasma concentration-time profile from time zero extrapolated to infinity time (<math>AUC_{inf}</math>), and half-life (<math>t_{1/2}</math>), if data permits, of pregabalin and oxycodone.</li> <li>Partial AUCs (<math>AUC_1</math>, <math>AUC_2</math>, <math>AUC_3</math>, <math>AUC_4</math>,</li> </ul>

Objectives	Endpoints
	<p>AUC<sub>8</sub>) of pregabalin and oxycodone.</p> <p><b>Safety Endpoints:</b></p> <ul style="list-style-type: none"> <li>• Vital signs include respiratory rate (RR), blood pressure (BP), pulse rate (PR).</li> <li>• Oxygen saturation of hemoglobin (SpO<sub>2</sub>).</li> <li>• Physical examination.</li> <li>• 12-lead electrocardiogram (ECG).</li> <li>• Clinical labs and AEs.</li> </ul>
<b>Tertiary/Exploratory:</b>	<b>Tertiary/Exploratory:</b>
<ul style="list-style-type: none"> <li>• Exposure-response relationship between pregabalin concentration and selected PD effect in the presence and absence of oxycodone.</li> <li>• To enable exploratory research through collection of banked biospecimens, unless prohibited by local regulations or ethics committee decision.</li> </ul>	<ul style="list-style-type: none"> <li>• Correlation between pregabalin concentrations and selected PD endpoints (Bipolar VAS for “Drug Liking”, Unipolar VAS for “High”, pupil diameter) in the presence and absence of oxycodone, as data permit.</li> <li>• Potential results from exploratory analysis of banked biospecimens (these results may or may not be generated in the context of the present study).</li> </ul>

## 4. STUDY DESIGN

### 4.1. Overall Design

This will be a randomized, double-blind, double-dummy, placebo- and active-controlled, 6-treatment, 6-period crossover, single-dose, Williams square design study in healthy male and/or female adult, non drug-dependent recreational opioid users. The study includes Screening, a Qualification Phase, a Treatment Phase and Follow-up. This study will randomize approximately 60 adult male and female (at least 20% female) participants (10 participants in each sequence) in the Treatment Phase to ensure at least 48 participants complete the Treatment Phase of the study. Dropouts for non-safety reasons may be replaced at the discretion of the Investigator in consultation with the Sponsor.

The following study visits are required, see Figure 1 and the SoA (Table 1 and Table 2):

1. Visit 1, Screening will occur within 28 days prior to Visit 2.
2. Visit 2, Qualification Phase will require inpatient stay at the Clinical Research Unit (CRU) for 3 nights:
  - a. Naloxone Challenge Phase, Day 0;
  - b. Drug Discrimination, Days 1 and 2 will require inpatient stay at the CRU for 2 nights;
  - c. End of Drug Discrimination requires an inpatient stay at the CRU overnight to ensure discharge occurs 24 hours after receiving oxycodone or placebo;
  - d. Participant will proceed to Visit 3 after at least 4-day washout but less than 28 days after the last dose of study intervention during qualification phase.
3. Visits 3 to 8, Treatment Phase will require a total of 18 overnight inpatient stays at the CRU:
  - a. Each visit will require an inpatient stay at the CRU of 3 nights;
  - b. Each visit will be separated by a washout period of at least 4 days. The washout period is calculated between two subsequent study drug administrations.
4. End of Study Assessments will be at the CRU to occur 48 hours after completing the last study drug dosing or time of early withdrawal.
5. For the entire study, 21 overnight inpatient stays will be required.

#### **4.1.1. Screening**

As shown in the SoA (Table 1), all participants will complete a Screening Visit with a standard medical screening to determine eligibility for this study. This visit (Visit 1) will occur within 28 days of the first dose in Qualification Phase of the study (Visit 2).

#### **4.1.2. Qualification Phase (Visit 2; Days 0 to 3)**

##### **4.1.2.1. Naloxone Challenge (Day 0)**

Eligible participants who successfully complete the Screening Visit will return to the study center to complete the naloxone challenge. The Naloxone Challenge (Day 0) will be performed to ensure the participant is not physically dependent on opioids.

During the Naloxone Challenge, all participants will receive intravenous (IV) naloxone 0.2 mg dose as an IV bolus, followed by an assessment for signs of opioid withdrawal. If there are no signs of opioid withdrawal within 30 seconds after administration, a second dose of 0.6 mg IV will be administered within 5 minutes of the first dose, followed by another assessment for signs of opioid withdrawal 5 minutes after the second naloxone dose. Only

participants who do not have signs and symptoms of opioid withdrawal, as assessed by the Clinical Opiate Withdrawal Scale (COWS score <5), ([Appendix 8](#)) will be eligible to proceed to the Drug Discrimination Phase.

Any participant demonstrating evidence of withdrawal (COWS score  $\geq 5$ ) on any assessment will not be eligible for further participation in the trial. The participant will be released from the study center when medically stable, as determined by the investigator. Symptoms reported in the COWS as a consequence of opioid withdrawal will not be collected as AEs unless they meet the criteria for a new AE or serious adverse event (SAE).

#### 4.1.2.2. Instrument Training

After successful completion of the Naloxone challenge, all eligible participants will undergo training on proper completion of the VAS instrument used to collect the PD endpoints. This will be done to ensure that participants fully understand how to perform the test, that they feel comfortable with the testing method being used for PD assessment and have attained a stable level of performance on the various performance-based measures. Detailed instructions for participant training will be provided in a separate study specific document. Retraining is permitted if required.

#### 4.1.2.3. Drug Discrimination (Days 1 to 3)

Following completion of the instrument training, the eligible participants will be evaluated for drug discrimination. The purpose of this phase is to select participants who report drug liking in response to a positive control and demonstrate a meaningfully different response from that produced by placebo.

The drug discrimination will be performed over 2 consecutive days. The treatments will be double blind. The participants will be randomly assigned to receive one of the blinded treatments (oxycodone 20 mg or placebo) on the first day and then receive the alternate treatment the next day according to a Williams square design, Table 3.

**Table 3. Schema for Qualification Phase**

Treatment Periods 1 and 2	
Day 1	Day 2
A	B
B	A

Treatment A: oxycodone 20 mg.

Treatment B: placebo.

Pharmacodynamic (VAS) and safety assessments (vital signs, pulse oximetry and respiratory rate) will be conducted at pre-dose and up to 5 hours post dosing. Continuing eligibility will be based on the participant's ability to:

- A placebo response between 40-60 points on a bipolar Drug Liking  $E_{\max}$  VAS of 0-100.



- The positive control should produce a score outside of the placebo range and should be at least 15 points greater than the placebo response.
- Tolerate study treatments safely; ie,  $\text{SpO}_2 \geq 90\%$ , no episodes of vomiting within the first 2 hours post-dose.
- Demonstrate general behavior suggestive that the participant could successfully complete the study, as judged by the study center staff.

Only those participants who produce these results may be enrolled in the study.

Participants will be discharged from the clinic on Day 3 of the drug discrimination phase, approximately 24 hours after the last dose of either oxycodone or placebo.

Following completion of the Drug Discrimination phase, the study data for each participant will be unblinded and a determination will be made by the Sponsor and Investigator (and/or designee) if the participants is eligible to continue in the study.

If participants fail to qualify, all AEs will be reported with no further study assessments.

#### **4.1.3. Treatment Phase (Visits 3 to 8)**

Participants who successfully complete the Naloxone Challenge and the Drug Discrimination Phase and who meet all the Randomization Criteria will be randomized into the Treatment Phase of this randomized, double-blind, placebo- and active-controlled, crossover study. Randomization can be done on Day 0, as needed, following completion of the Naloxone Challenge test.

On Day 1 of each of the 6 periods, which will be separated by a washout of at least 4 days, participants will receive an oral dose of either pregabalin 300 mg or 450 mg alone or in combination with a 20 mg dose of oxycodone IR or 20 mg monotherapy of oxycodone HCl or placebo. Study treatments will be administered under fasted conditions (overnight fast and no food until 4 hours after dosing). Water will be allowed without restriction until 1 hour prior to dosing and 1 hour after dosing.

Physiological and subjective scales will be used to assess the potential for abuse of the concomitant use of pregabalin with oxycodone HCl and blood samples for the analysis of pregabalin and oxycodone HCl in plasma will be obtained pre-dose (30 minutes prior to dosing) and post-dose as outlined in the [Schedule of Activities \(SoA\)](#). Vital signs including respiratory rate, pulse oximetry and pupillometry will be evaluated and tolerability and safety will be assessed for all treatments by monitoring AEs.

#### **4.2. Scientific Rationale for Study Design**

There is a need to systematically evaluate the abuse potential of pregabalin taken concomitantly with an opioid, such as oxycodone, investigating a range of pregabalin dose (the highest therapeutic and supra-therapeutic) combined with the opioid in healthy non-drug dependent population with drug abuse experience. Therefore, this clinical trial will evaluate the pregabalin/opioid combinations in a cross-over design with comparison to placebo,

pregabalin alone, and a moderate dose of the opioid taken alone as a positive control. Hence the study design will employ a 6-sequence, 6-period, cross-over design which will include the placebo, positive control (20 mg oxycodone IR), two doses of pregabalin alone (300 mg and 450 mg) and each pregabalin dose in combination with 20 mg oxycodone IR to allow for the various comparisons to be systematically evaluated. The washout period will be least 4 days minimizing the carry over effects of the treatments, especially if additive or synergistic effects are noted with the combination treatments. PK will be evaluated to allow for an exploratory correlation of pharmacodynamic effects.

Banked biospecimens will be collected for exploratory pharmacogenomic/genomic/biomarker analyses and retained in the Biospecimen Banking System (BBS), which makes it possible to better understand the investigational product's mechanism of action and to seek explanations for differences in, for example, exposure, tolerability, safety, and/or efficacy not anticipated prior to the beginning of the study.

#### **4.3. Justification for Dose**

The highest therapeutic dose of pregabalin in adults for postherpetic neuralgia and neuropathic pain is 300 mg administered 2 times a day (600 mg/day). This dose of pregabalin was well tolerated in healthy adult participants following a single and multiple dosing and showed acceptable safety profile. The most common adverse events for 300 mg dose were dizziness and somnolence (>50% of participants).

Supratherapeutic dose 450 mg of pregabalin was the highest dose of pregabalin evaluated in previous abuse liability clinical study. This dose of pregabalin (450 mg) dose was well tolerated in 15 healthy adult recreational drug users. Only 5 out of 15 participants reported adverse events that are mild in nature. The most common adverse events were headache, confusion, and infection.<sup>5</sup>

Therefore, the highest therapeutic single dose, 300 mg and a supratherapeutic dose of 450 mg (1.5x of the highest therapeutic dose) will be selected to determine the abuse potential of pregabalin when administered concomitantly with oxycodone HCl 20 mg in this study.

A single 20 mg dose of oxycodone HCl is selected based on the request from the United States (US) Food and Drug Administration (FDA) for concomitant administration with pregabalin and as positive control. During concomitant treatment with pregabalin, 20 mg oxycodone could allow for assessing potential potentiation effect of pregabalin to oxycodone is significantly reduced. Consequently, 20 mg dose of oxycodone, which is expected to have a lower VAS  $E_{max}$  score will be used. In addition, a 20 mg oxycodone dose has been historically used as a positive control in abuse. Based on published studies, the reported mean "Drug Liking" bipolar VAS  $E_{max}$  scores for a 20 mg oxycodone dose were 68.0 and 76.5.<sup>15,16</sup>



#### **4.4. End of Study Definition**

A participant is considered to have completed the study if he/she has completed all phases of the study including the last scheduled procedure shown in the.

The end of the study is defined as the date of the last visit of the last participant in the study.

#### **5. STUDY POPULATION**

This study can fulfill its objectives only if appropriate participants are enrolled. The following eligibility criteria are designed to select participants for whom participation in the study is considered appropriate. All relevant medical and nonmedical conditions should be taken into consideration when deciding whether a participant is suitable for this protocol.

Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as protocol waivers or exemptions, is not permitted.

##### **5.1. Inclusion Criteria**

Participants are eligible to be included in the study only if all the following criteria apply:

###### **Age and Sex:**

1. Male and female participants must be 18 to 55 years of age, inclusive, at the time of screening. There must be no less than 20% female participants in the Treatment Phase.
  - Refer to [Appendix 4](#) for reproductive criteria for male ([Section 10.4.1](#)) and female ([Section 10.4.2](#)) participants.

###### **Type of Participant and Disease Characteristics:**

2. Male and female participants who are overtly healthy. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, vital signs, 12-lead ECG, and/or clinical laboratory tests.
3. Participants must have drug abuse experience with opioids; ie, must have used opioids for non-therapeutic purposes (ie, for psychoactive effects) on at least 10 occasions within the last year and at least once in the 8 weeks before the Screening Visit (Visit 1).
4. Participants must satisfactorily complete both the Naloxone Challenge and the Drug Discrimination.
5. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.

**Weight:**

6. Body mass index (BMI) of 17.5 to 34 kg/m<sup>2</sup>, inclusive; and a total body weight  $\geq$ 50 kg (110 lb).

**Informed Consent:**

7. Capable of giving signed informed consent as described in [Appendix 1](#), which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in this protocol.

**5.2. Exclusion Criteria**

Participants are excluded from the study if any of the following criteria apply:

**Medical Conditions:**

1. Current or past diagnosis of any type of drug dependence within the past year. Diagnosis of substance and/or alcohol dependence (excluding caffeine and nicotine) will be assessed by the Investigator using the Diagnostic and Statistical Manual-4 (DSM-4) criteria performed at Screening. Current drug use will be allowed if the candidate can produce a negative urine sample and are free of any signs/symptoms of withdrawal. The candidate will be informed if they have a positive breathalyzer test.
2. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
3. Any condition possibly affecting drug absorption (eg, gastrectomy) excluding cholecystectomy within 1 year prior to study.
4. Abnormal baseline EtCO<sub>2</sub> <35mm Hg or >45 mm Hg.
5. Clinical or laboratory evidence of active hepatitis A infection or a history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C and/or positive testing for HIV, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C antibody (HCVAb).
6. Participants with active suicidal ideation or suicidal behavior within 5 year prior to Screening as determined through the use of the Columbia-Suicide Severity Rating Scale (C-SSRS) or active ideation identified at Screening or on Day 0.

7. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
8. Patients with: sleep apnea, myasthenia gravis and glaucoma.

**Prior/Concomitant Therapy:**

9. Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of investigational product. (Refer to [Section 6.5](#) for additional details).
10. Herbal supplements and herbal medications must be discontinued at least 28 days prior to the first dose of study medication.

**Prior/Concurrent Clinical Study Experience:**

11. Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives (whichever is longer) preceding the first dose of investigational product used in this study.

**Diagnostic Assessments:**

12. Positive urine drug screen (UDS) for substances of abuse at each admission in the Qualification and Treatment Phase, excluding tetrahydrocannabinol (THC). If a participant presents with a positive UDS excluding THC at any admission or any visit, the investigator, at his/her discretion, may reschedule a repeat of UDS until the UDS is negative, excluding THC, before the participant is permitted to participate in any phase of the study.
13. Unable to abstain from using THC during the Qualification and Treatment Phase of the study.
14. Has participated in, is currently participating in, or is seeking treatment for substance-and/or alcohol-related disorders (excluding nicotine and caffeine).
15. Has a positive alcohol breathalyzer or urine test at each admission to the study center during qualification and treatment phase. Positive results may be repeated and/or participants re-scheduled at the Investigator's discretions.
16. Participants are heavy smokers or users of other types of nicotine products (>20 cigarettes equivalents per day).

17. Participants are unable to abstain from smoking for at least 2 hours before and at least 8 hours after study drug administration.
18. Screening sitting blood pressure (BP)  $\geq 140$  mm Hg (systolic) or  $\geq 90$  mm Hg (diastolic), following at least 5 minutes rest. If BP is  $\geq 140$  mm Hg (systolic) or  $\geq 90$  mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility. Repeated BP tests should be spaced at least 5 minutes apart.
19. Baseline (screening) 12-lead electrocardiogram (ECG) that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (eg, baseline corrected QT (QTc) interval as determined by the Fridericia method (QTcF)  $> 450$  msec, complete left bundle branch block [LBBB], signs of an acute or indeterminate-age myocardial infarction, ST-T interval changes suggestive of myocardial ischemia, second- or third-degree atrioventricular [AV] block, or serious bradyarrhythmias or tachyarrhythmias). If the baseline uncorrected QT interval is  $> 450$  msec, this interval should be rate-corrected using the Fridericia method and the resulting QTcF should be used for decision making and reporting. If QTcF exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTcF or QRS values should be used to determine the participant's eligibility. Computer-interpreted ECGs should be overread by a physician experienced in reading ECGs before excluding participants.
20. Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study-specific laboratory and confirmed by a single repeat test, if deemed necessary:
  - Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level  $\geq 1.5 \times$  upper limit of normal (ULN);
  - Total bilirubin level  $\geq 1.5 \times$  ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is  $\leq$  ULN.

**Other Exclusions:**

21. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
22. History of sensitivity to heparin or heparin-induced thrombocytopenia.
23. Unwilling or unable to comply with the criteria in the Lifestyle Considerations section of this protocol.
24. History of hypersensitivity to pregabalin or oxycodone or any of the components in the formulation of the study products.

25. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or Sponsor employees, including their family members, directly involved in the conduct of the study.

### **5.3. Lifestyle Considerations**

The following guidelines are provided:

#### **5.3.1. Meals and Dietary Restrictions**

- Participants must abstain from all food and drink (except water) at least 4 hours prior to any safety laboratory evaluations and at least 10 hours prior to the collection of the pre-dose PK sample for fasted treatment.
- Water is permitted until 1 hour prior to investigational product administration. Water may be consumed without restriction beginning 1 hour after dosing. Noncaffeinated drinks (except grapefruit or grapefruit-related citrus fruit juices—see below) may be consumed with meals and the evening snack.
- Lunch will be provided approximately 4 hours after dosing.
- Dinner will be provided approximately 9 to 10 hours after dosing.
- An evening snack may be permitted.
- Participants will refrain from consuming red wine, grapefruit, or grapefruit-related citrus fruits (eg, Seville oranges, pomelos, fruit juices) from 7 days prior to the first dose of investigational product until collection of the final PK blood sample.
- While participants are confined, their total daily nutritional composition should be approximately 55% carbohydrate, 30% fat, and 15% protein. The daily caloric intake per participant should not exceed approximately 3200 kcal.

#### **5.3.2. Caffeine, Alcohol, and Tobacco**

- Participants will abstain from caffeine-containing products for 24 hours prior to the start of dosing until collection of the final PK sample of each study period.
- Participants will abstain from alcohol for 24 hours prior to admission to the clinical research unit (CRU) and continue abstaining from alcohol until collection of the final PK sample of each study period. Participants may undergo an alcohol breath test or blood alcohol test at the discretion of the investigator.

- Participants will not be permitted to smoke from at least 2 hours before until at least 8 hours after dosing in the Qualification and Treatment Phases. At all other times while housed in the study center smoking may be permitted in short breaks at the study center staff's discretion. The use of oral or chewed tobacco and/or nicotine-containing products (including topical patches) is not permitted from at least 2 hours before and at least 8 hours after study drug administration.

### **5.3.3. Activity**

- Participants will abstain from strenuous exercise (eg, heavy lifting, weight training, calisthenics, aerobics) for at least 48 hours prior to each blood collection for clinical laboratory tests. Walking at a normal pace will be permitted.

### **5.3.4. Contraception**

The investigator or his or her designee, in consultation with the participant, will confirm that the participant has selected an appropriate method of contraception for the individual participant and his or her partner(s) from the permitted list of contraception methods (see [Appendix 4](#)) and will confirm that the participant has been instructed in its consistent and correct use. At time points indicated in the [Schedule of Activities \(SoA\)](#), the investigator or designee will inform the participant of the need to use highly effective contraception consistently and correctly and document the conversation and the participant's affirmation in the participant's chart (participants need to affirm their consistent and correct use of at least 1 of the selected methods of contraception). In addition, the investigator or designee will instruct the participant to call immediately if the selected contraception method is discontinued or if pregnancy is known or suspected in the participant or partner.

### **5.4. Screen Failures**

Screen failures are defined as participants who consent to participate in the clinical study but are not subsequently entered in the Qualification Phase. Screen failure data are collected and remain as source and are not reported to the clinical database.

## **6. STUDY INTERVENTION**

Study intervention is defined as any investigational intervention(s), marketed product(s), placebo, or medical device(s) intended to be administered to a study participant according to the study protocol.

For the purposes of this protocol, the term investigational product may be used synonymously with study intervention.

### **6.1. Study Interventions Administered**

For this study, the investigational products are Lyrica® and oxycodone HCl.

Lyrica® and oxycodone HCl will be provided by Upjohn US 1 LLC.

### **6.1.1. Administration**

Following an overnight fast of at least 10 hours, participants will receive investigational product at approximately 08:00 hours (plus or minus 2 hours). Investigator site personnel will administer investigational product during each period with ambient temperature water to a total volume of approximately 240 mL. Detailed instructions on preparation of all study treatments, including steps to maintain the double blind, will be provided separately in Drug Administration Instructions (DIA).

In order to standardize the conditions on PK sampling days, all participants will be required to refrain from lying down (except when required for ECG measurements), eating, and drinking beverages other than water during at least the first 4 hours after dosing. Water may only be consumed at least 1 hour following dosing.

### **6.2. Preparation/Handling/Storage/Accountability**

1. The investigator or designee must confirm appropriate temperature conditions have been maintained during transit for all study interventions received and any discrepancies are reported and resolved before use of the study intervention, as applicable for temperature-monitored shipments.
2. Only participants enrolled in the study may receive study intervention and only authorized site staff may supply or administer study intervention. All study interventions must be stored in a secure, environmentally controlled, and monitored (manual or automated recording) area in accordance with the labeled storage conditions with access limited to the investigator and authorized site staff. At a minimum, daily minimum and maximum temperatures for all site storage locations must be documented and available upon request. Data for nonworking days must indicate the minimum and maximum temperature since previously documented for all site storage locations upon return to business.
3. The investigator, institution, or the head of the medical institution (where applicable) is responsible for study intervention accountability, reconciliation, and record maintenance (ie, receipt, reconciliation, and final disposition records). All study interventions will be accounted for using an investigational product accountability form/record.
4. Further guidance and information for the final disposition of unused study interventions are provided in the investigational product (IP) manual.
5. Any storage conditions stated in the SRSD will be superseded by the storage conditions stated on the product label.
6. Study interventions should be stored in their original containers and in accordance with the labels.
7. Deviations from the storage requirements, including any actions taken, must be documented and reported to Sponsor upon discovery. The site should actively pursue



options for returning the study intervention to the storage conditions described in the labeling, as soon as possible. Once an excursion is identified, the study intervention must be quarantined and not used until Sponsor provides permission to use the study intervention. It will not be considered a protocol deviation if Sponsor approves the use of the study intervention after the temperature excursion. Use of the study intervention prior to Sponsor approval will be considered a protocol deviation. Specific details regarding the definition of an excursion and information the site should report for each excursion will be provided to the site in the IP manual.

8. The sponsor or designee will provide guidance on the destruction of unused study intervention (eg, at the site). If destruction is authorized to take place at the investigator site, the investigator must ensure that the materials are destroyed in compliance with applicable environmental regulations, institutional policy, and any special instructions provided by Sponsor, and all destruction must be adequately documented.

#### **6.2.1. Preparation and Dispensing**

Within this protocol, preparation refers to the investigator site activities performed to make the investigational product ready for administration or dispensing to the participant/caregiver by qualified staff. Dispensing is defined as the provision of investigational product, concomitant treatments, and accompanying information by qualified staff member(s) to a healthcare provider, participant, or caregiver in accordance with this protocol. Local health authority regulations or investigator site guidelines may use alternative terms for these activities.

Investigational products will be prepared at the CRU in the individual dosing containers by 2 operators, at least 1 of whom is an appropriately qualified and experienced member of the study staff (eg, physician, nurse, physician's assistant, nurse practitioner, pharmacy assistant/technician, or pharmacist). The investigational products will be provided in appropriate containers and labeled in accordance with Sponsor regulations and the clinical site's labeling requirements.

### **6.3. Measures to Minimize Bias: Randomization and Blinding**

#### **6.3.1. Allocation to Investigational Product**

At screening, participants will be assigned a subject screening identification number (SSID) via an automated Interactive Response Technology (IRT) or equivalent system.

Following screening the participants will be randomly assigned a qualification randomization number (QRN) via the IRT or equivalent system using a 1:1 randomization. The QRN will be retained throughout the study and will correspond to the blinded qualification phase.

After satisfactory completion of the qualification phase, participants will randomly be assigned a study randomization number (SRN) via the IRT or equivalent system using a 1:1 randomization for the treatment phase. The SRN will be retained throughout the study and will correspond to the blinded treatment sequence.



### **6.3.2. Breaking the Blind**

The investigator site, study monitor(s), and Sponsor personnel will be blinded to study treatment. The site will have an unblinded pharmacist for preparation of the study drugs. The unblinded pharmacist or unblinded designee at the study center will be responsible for ensuring blinding procedure oversight at the study center, according to the study center guidelines. The unblinded pharmacist will not be able to perform any other duties for this study outside of the requirements of ensuring the blind.

At the completion of the Drug Discrimination Phase, the Investigator and/or designee will un-blind the participant's treatment sequence in order for the Investigator and Sponsor personnel to assess participant eligibility to continue to the Treatment Phase of the study. Additional information regarding the criteria for Drug Discrimination can be found in. Treatment data during the Treatment Phase of the study will remain blinded throughout the course of treatment until the study database has been locked. Unblinding during the Treatment Phase will not occur unless medically necessary for participant safety.

The IRT will be programmed with blind breaking instructions. In case of an emergency, the investigator has the sole responsibility for determining if unblinding of a participant's treatment assignment is warranted. Participant safety must always be the first consideration in making such a determination. If the investigator decides that unblinding is warranted, the investigator should make every effort to contact the sponsor or medical monitor prior to unblinding a participant's treatment assignment unless this could delay further management of the participant. If a participant's treatment assignment is unblinded, the sponsor must be notified within 24 hours after breaking the blind. The date and reason that the blind was broken must be recorded in the source documentation and data collection tool (DCT).

The study specific IRT reference manual and IP manual will provide the contact information and further details on the use of the IRT system.

### **6.4. Study Intervention Compliance**

Investigational product will be administered under the supervision of investigator site personnel. The oral cavity of each participant will be examined following dosing to ensure the investigational product was taken.

### **6.5. Concomitant Therapy**

Use of prescription or nonprescription drugs and dietary and herbal supplements are prohibited within 7 days or 5 half-lives (whichever is longer) prior to the first dose of investigational product. Limited use of nonprescription medications that are not believed to affect participant safety or the overall results of the study may be permitted on a case-by-case basis following approval by the sponsor.

Hormonal contraceptives that meet the requirements of this study are allowed to be used in participants who are WOCBP (see [Appendix 4](#)).

All concomitant treatments taken during the study must be recorded with indication, daily dose, and start and stop dates of administration. All participants will be questioned about concomitant treatment at each clinic visit.

Treatments taken within 28 days before the first dose of investigational product will be documented as a prior treatment. Treatments taken after the first dose of investigational product will be documented as concomitant treatments.

## **6.6. Dose Modification**

Dose modification will not be allowed in this single dose study.

## **6.7. Emergency Intervention**

- The investigational site shall have a fully equipped “crash cart” and advanced cardiac life support certified staff present during the entire study.
- Acute pregabalin and/or oxycodone toxicity can be manifested as drowsiness, respiratory depression, and somnolence progressing to stupor, coma or death. In the event that acute pregabalin and/or oxycodone toxicity occurs, primary attention shall be given to re-establishment and/or maintenance of a patent airway and situation of assisted or controlled ventilation.
- Other supportive measures including the use of oxygen and vasopressors should be employed in the standard management of circulatory shock if it occurs in the event of pregabalin and/or oxycodone toxicity, or other/further treatments as appropriate.

## **6.8. Intervention After the End of the Study**

No intervention will be provided to study participants at the end of the study.

## **7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL**

### **7.1. Discontinuation of Study Intervention**

In rare instances, it may be necessary for a participant to permanently discontinue investigational product. If investigational product is permanently discontinued, the participant will not remain in the study. See the SoA (Table 2) for data to be collected at the time of early termination/discontinuation of investigational product.

### **SpO<sub>2</sub> Changes**

Participants with an absolute change (drop) in SpO<sub>2</sub> of 4% should be withdrawn from the study and recorded as an AE.

### **EtCO<sub>2</sub> Changes**

Participants with an absolute change (increase) in EtCO<sub>2</sub> of 10 mm Hg should be withdrawn from the study and recorded as an AE.

## ECG Changes

If the ECG of a participant meets the bulleted criteria below, then two more ECGs will be performed. If the average of the three ECGs meets the bulleted criteria below, the participant is to be withdrawn from the study.

- QT, QTcF (corrected QT [Fridericia method]) >500 msec.
- Change from baseline: QTcF >60 msec.

If a clinically significant finding is identified (including, but not limited to, changes from baseline in QTcF after enrollment), the investigator or qualified designee will determine if the participant can continue in the study and if any change in participant management is needed. This review of the ECG printed at the time of collection must be documented. Any new clinically relevant finding should be reported as an AE.

See the SoA (Table 2) for data to be collected at the time of intervention discontinuation and follow-up and for any further evaluations that need to be completed.

## Potential Cases of Acute Kidney Injury

Abnormal values in serum creatinine (SCr) concurrent with presence or absence of increase in blood urea nitrogen (BUN) that meet the criteria below, in the absence of other causes of kidney injury, are considered potential cases of acute kidney injury and should be considered important medical events.

An increase of  $\geq 0.3$  mg/dL (or  $\geq 26.5$   $\mu\text{mol/L}$ ) in SCr level relative to the participant's own baseline measurement should trigger another assessment of SCr as soon as practically feasible, preferably within 48 hours from awareness.

If the second assessment (after the first observations of  $\geq 0.3$  mg/dL [or  $\geq 26.5$   $\mu\text{mol/L}$ ] in SCr relative to the participant's own baseline measurement) is  $\geq 0.4$  mg/dL (or  $\geq 35.4$   $\mu\text{mol/L}$ ), the participant should be discontinued from the study and adequate, immediate, supportive measures taken to correct apparent acute kidney injury.

Participants should return to the investigator site and be evaluated as soon as possible, preferably within 48 hours from awareness of the second assessment confirming abnormal SCr result. This evaluation should include laboratory tests, detailed history, and physical assessment. In addition to repeating SCr, laboratory tests should include serum BUN, serum creatine kinase, and serum electrolytes (including at a minimum potassium, sodium, phosphate/phosphorus, and calcium), in addition to urinary dipstick, urine microscopic examination, and urinary indices. All cases confirmed on repeat testing as meeting the laboratory criteria for acute kidney injury, with no other cause(s) of laboratory abnormalities identified, should be considered potential cases of drug-induced kidney injury irrespective of availability of all the results of the investigations performed to determine etiology of the abnormal SCr. If  $\geq 2$  healthy participants in a given period are noted to have 2 consecutive

SCr results of  $\geq 0.3$  mg/dL (or  $\geq 26.5$   $\mu\text{mol/L}$ ), an assessment of whether the finding may be considered an adverse drug reaction should be undertaken.

## **Pregnancy**

In the case of a positive confirmed pregnancy, the participant will be withdrawn from the study.

## **7.2. Participant Discontinuation/Withdrawal from the Study**

A participant may withdraw from the study at any time at his/her own request or may be withdrawn at any time at the discretion of the investigator for safety, behavioral, compliance, or administrative reasons.

At the time of discontinuing from the study, if possible, an early discontinuation visit should be conducted. See the SoA (Table 2) for assessments to be collected at the time of study discontinuation and follow-up and for any further evaluations that need to be completed.

The early discontinuation visit applies only to participants who are randomized and then are prematurely withdrawn from the study. Participants should be questioned regarding their reason for withdrawal.

The participant will be permanently discontinued both from the study intervention and from the study at that time.

If a participant withdraws from the study, he/she may request destruction of any remaining samples, but data already generated from the samples will continue to be available and may be used to protect the integrity of existing analyses. The investigator must document any such requests in the site study records.

If the participant withdraws from the study and withdraws consent (see below) for disclosure of future information, no further evaluations should be performed, and no additional data should be collected. The sponsor may retain and continue to use any data collected before such withdrawal of consent.

When a participant withdraws from the study because of an SAE, the SAE must be recorded on the Case Report Form (CRF) and reported on the Clinical Trial (CT) SAE Report.

Lack of completion of all or any of the withdrawal/early termination procedures will not be viewed as protocol deviations so long as the participant's safety was preserved.

## **Withdrawal of Consent:**

Participants who request to discontinue receipt of study treatment will remain in the study and must continue to be followed for protocol-specified follow-up procedures. The only exception to this is when a participant specifically withdraws consent for any further contact with him or her or persons previously authorized by the participant to provide this information. Participants should notify the investigator in writing of the decision to

withdraw consent from future follow-up, whenever possible. The withdrawal of consent should be explained in detail in the medical records by the investigator, as to whether the withdrawal is only from further receipt of investigational product or also from study procedures and/or posttreatment study follow-up, and entered on the appropriate CRF page. In the event that vital status (whether the participant is alive or dead) is being measured, publicly available information should be used to determine vital status only as appropriately directed in accordance with local law.

### **7.3. Lost to Follow up**

A participant will be considered lost to follow-up if he or she repeatedly fails to return for scheduled visits and is unable to be contacted by the study site.

The following actions must be taken if a participant fails to return to the clinic for a required study visit:

- The site must attempt to contact the participant and reschedule the missed visit as soon as possible and counsel the participant on the importance of maintaining the assigned visit schedule and ascertain whether the participant wishes to and/or should continue in the study;
- Before a participant is deemed lost to follow-up, the investigator or designee must make every effort to regain contact with the participant (where possible, 3 telephone calls and, if necessary, a certified letter to the participant's last known mailing address or local equivalent methods). These contact attempts should be documented in the participant's medical record;
- Should the participant continue to be unreachable, he/she will be considered to have withdrawn from the study.

Discontinuation of specific sites or of the study as a whole is handled as part of [Appendix 1](#).

## **8. STUDY ASSESSMENTS AND PROCEDURES**

Participants will be screened within 28 days prior to first dose during Qualification Phase to confirm that they meet the study population criteria for the study. The investigator (or an appropriate delegate at the investigator site) must obtain a signed and dated ICD before performing any study-specific procedures. If the time between screening and dosing exceeds 28 days as a result of unexpected delays (eg, delayed drug shipment), then participants do not require rescreening if the laboratory results obtained prior to first dose administration meet eligibility criteria.

A participant who qualified for this protocol but did not enroll from an earlier cohort/group may be used in a subsequent cohort/group without rescreening, provided laboratory results obtained prior to the first dose administration meet eligibility criteria for this study. In addition, other clinical assessments or specimen collections, eg, banked biospecimens, may be used without repeat collection, as appropriate.

Study procedures and their timing are summarized in the [Schedule of Activities \(SoA\)](#). Protocol waivers or exemptions are not allowed.

Immediate safety concerns should be discussed with the sponsor immediately upon occurrence or awareness to determine if the participant should continue or discontinue study intervention.

Adherence to the study design requirements, including those specified in the [Schedule of Activities \(SoA\)](#), is essential and required for study conduct.

All screening evaluations must be completed and reviewed to confirm that potential participants meet all eligibility criteria. The investigator will maintain a screening log to record details of all participants screened and to confirm eligibility or record reasons for screening failure, as applicable.

Every effort should be made to ensure that protocol-required tests and procedures are completed as described. However, it is anticipated that from time to time there may be circumstances outside the control of the investigator that may make it unfeasible to perform the test. In these cases, the investigator must take all steps necessary to ensure the safety and well-being of the participant. When a protocol-required test cannot be performed, the investigator will document the reason for the missed test and any corrective and preventive actions that he or she has taken to ensure that required processes are adhered to as soon as possible. The study team must be informed of these incidents in a timely manner.

Vital signs (HR, BP, RR), SpO<sub>2</sub> and EtCO<sub>2</sub> and AEs will be determined within 10 minutes before the nominal time points.

PD measures (ie, VAS) will be administered at the nominal time points ( $\pm 5$  minutes), followed by pupillometry.

PK sample collection will occur within approximately 5 minutes of completion of pupillometry assessments and the actual sample collection time will be recorded.

All pre-dose measures will be obtained within 30 minutes before dosing.

If an intravenous (IV) catheter is utilized for blood sample collections, baseline ECGs and/or vital sign assessments (pulse rate and BP) should be collected prior to the insertion of the catheter.

For samples being collected and shipped, detailed collection, processing, storage, and shipment instructions and contact information will be provided to the investigator site prior to initiation of the study.

The total blood sampling volume for individual participants in this study is approximately 535 mL. The actual collection times of blood sampling may change. Additional blood samples may be taken for safety assessments at times specified by Sponsor, provided the



total volume taken during the study does not exceed 550 mL during any period of 60 consecutive days.

To prepare for study participation, participants will be instructed on the information in the Lifestyle Considerations and Concomitant Therapy sections of the protocol.

### **8.1. Efficacy Assessments**

Not applicable.

### **8.2. Safety Assessments**

Planned time points for all safety assessments are provided in the [Schedule of Activities \(SoA\)](#). Unscheduled clinical laboratory measurements may be obtained at any time during the study to assess any perceived safety concerns.

#### **8.2.1. Physical Examinations**

A complete physical examination will include, at a minimum, head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, and gastrointestinal, musculoskeletal, and neurological systems.

A brief physical examination will include, at a minimum, assessments of general appearance, the respiratory and cardiovascular systems, and participant-reported symptoms.

Physical examinations may be conducted by a physician, trained physician's assistant, or nurse practitioner as acceptable according to local regulation.

Height and weight will also be measured and recorded as per the [Schedule of Activities \(SoA\)](#). For measuring weight, a scale with appropriate range and resolution is used and must be placed on a stable, flat surface. Participants must remove shoes, bulky layers of clothing, and jackets so that only light clothing remains. They must also remove the contents of their pockets and remain still during measurement of weight.

#### **8.2.2. Vital Signs**

Sitting BP will be measured with the participant's arm supported at the level of the heart, and recorded to the nearest mm Hg after approximately 5 minutes of rest. The same arm (preferably the dominant arm) will be used throughout the study. Participants should be instructed not to speak during measurements.

The same properly sized and calibrated BP cuff will be used to measure BP each time. The use of an automated device for measuring BP is acceptable. Pulse rate and oxygen saturation will be measured with a pulse oximeter. When the timing of these measurements coincides with a blood collection, BP, pulse oximetry and respiratory rate should be obtained prior to the nominal time of the blood collection.

Heart and respiratory rates, oxygen saturation, diastolic and systolic blood pressure will be monitored post-drug (see [SoA](#)). These measures are done in abuse liability testing to ensure safety.

Additional collection times, or changes to collection times, of BP, pulse oximetry and respiratory rates will be permitted, as necessary, to ensure appropriate collection of safety data.

The procedure for collecting postural or orthostatic data will be:

- Assess BP after the participant is in the supine position for a minimum of 5 minutes;
- Have the participant stand up for 2 minutes;
- Assess BP after the participant is in the standing position for approximately 2 minutes.

Orthostatic hypotension is defined as a decrease of  $\geq 20$  mm Hg for systolic BP or  $\geq 10$  mm Hg for diastolic BP 2 minutes after standing from a supine position. Orthostatic hypotension may be symptomatic or asymptomatic. Symptoms of orthostatic hypotension are those that develop upon assuming the erect posture from a supine position and may include: lightheadedness, dizziness, blurred vision, weakness, fatigue, cognitive impairment, nausea, palpitations, tremulousness, headache, and/or neck ache.

If a participant has symptoms suggestive of orthostasis, but not documented orthostatic hypotension, repeated measurements of supine/standing BP should be obtained. Lesser degrees of BP reduction may still be considered clinically significant if the participant becomes symptomatic upon standing, especially in the presence of a significant increase in pulse rate ( $\geq 30$  beats per minute [bpm]).

#### **8.2.2.1. Respiratory Monitoring**

Respiratory rate (RR, breaths/min), pulse oximetry, tidal volume (VT, mL) and end-tidal carbon dioxide (ETCO<sub>2</sub>, mm Hg) will be measured continuously, pre-dose to 8 hours and then for 5 minutes at 12 hours and 24 hours post-dose during the Treatment Phase (see [Schedule of Activities \(SoA\)](#)).

#### **8.2.2.2. Temperature**

Temperature will be measured orally or with a temporal infrared scanner. No eating, drinking, or smoking is allowed for 15 minutes prior to the oral measurement.

#### **8.2.3. Pupillometry**

Both pupils will be measured with a calibrated pupillometer under mesopic lighting during the Qualification Phase, predose and postdose, and during the Treatment Phase, predose and post dose at time points specified in the [Schedule of Activities \(SoA\)](#).



Pupillometry will be monitored before dosing and 0.25, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36 and 48 hours post-drug. These measures are done in abuse liability testing to verify dosing.

#### **8.2.4. Electrocardiograms**

Twelve (12)-Lead ECGs should be collected at times specified in the [Schedule of Activities \(SoA\)](#) section of this protocol using an ECG machine that automatically calculates the heart rate and measures PR, QT, and QTc intervals and QRS complex. All scheduled ECGs should be performed after the participant has rested quietly for at least 10 minutes in a supine position.

To ensure safety of the participants, a qualified individual at the investigator site will make comparisons to baseline measurements. Additional ECG monitoring will occur if a) a post-dose QTcF interval is increased by  $\geq 30$  msec from the baseline **and** is  $>450$  msec; or b) an absolute QT value is  $\geq 500$  msec for any scheduled ECG. If either of these conditions occurs, then 2 additional ECGs will be collected approximately 2 to 4 minutes apart to confirm the original measurement. If the QTcF values from these repeated ECGs remain above the threshold value, then a single ECG must be repeated at least hourly until QTc values from 2 successive ECGs fall below the threshold value that triggered the repeat measurement.

If a post-dose QTcF interval remains  $\geq 30$  msec from the baseline **and** is  $>450$  msec; or b) an absolute QT value is  $\geq 500$  msec for any scheduled ECG for greater than 4 hours (or sooner, at the discretion of the investigator), or QTcF intervals get progressively longer, the participant should undergo continuous ECG monitoring. A cardiologist should be consulted if QTcF intervals do not return to less than the criterion listed above after 8 hours of monitoring (or sooner, at the discretion of the investigator).

In some cases, it may be appropriate to repeat abnormal ECGs to rule out improper lead placement as contributing to the ECG abnormality. It is important that leads be placed in the same positions each time in order to achieve precise ECG recordings. If a machine-read QTc value is prolonged, as defined above, repeat measurements may not be necessary if a qualified medical provider's interpretation determines that the QTcF values are in the acceptable range.

ECG values of potential clinical concern are listed in [Appendix 7](#).

##### **8.2.4.1. Continuous Cardiac Monitoring by Telemetry**

Continuous cardiac monitoring will be performed during the Treatment phase as noted in the SoA (Table 2). The time, duration, and description of any clinically significant abnormal rhythm will be reported as an adverse event using [Appendix 7](#) as a guide as to what is generally considered to be a drug-related adverse event of potential clinical concern.

### **8.2.5. Clinical Safety Laboratory Assessments**

See [Appendix 2](#) for the list of clinical safety laboratory tests to be performed and the [Schedule of Activities \(SoA\)](#) for the timing and frequency.

The investigator must review the laboratory report, document this review, and record any clinically relevant changes occurring during the study in the AE section of the CRF. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.

All laboratory tests with values considered clinically significantly abnormal during participation in the study or within 28 to 35 days after the last dose of study intervention should be repeated until the values return to normal or baseline or are no longer considered clinically significant by the investigator or medical monitor.

If such values do not return to normal/baseline within a period of time judged reasonable by the investigator, the etiology should be identified and the sponsor notified.

All protocol-required laboratory assessments, as defined in [Appendix 2](#), must be conducted in accordance with the laboratory manual and the [Schedule of Activities \(SoA\)](#).

If laboratory values from non-protocol-specified laboratory assessments performed at the institution's local laboratory require a change in participant management or are considered clinically significant by the investigator (eg, SAE or AE or dose modification), then the results must be recorded in the CRF.

Participants may undergo random urine drug testing at the discretion of the investigator. Drug testing conducted prior to dosing must be negative for participants to receive investigational product.

### **8.2.6. Suicidal Ideation and Behavior Risk Monitoring**

#### **8.2.6.1. Columbia Suicidality Severity Rating Scale (C-SSRS)**

The Columbia Suicide-Severity Rating Scale (C-SSRS) will be collected at timepoints on the [Schedule of Activities \(SoA\)](#). The C-SSRS is being used in the current study to provide a summary measure of suicidal ideation and behavior risks. This scale is to be completed by trained staff. Training materials on the scale will be provided to investigator sites by Sponsor.

#### **8.2.6.2. Risk Assessment During Screening**

The Investigator will review the results of the C-SSRS (baseline), and medical history. The following criteria would indicate a potential suicide risk:

- Suicidal ideation associated with actual intent and/or method and/or plan and/or action (eg, self-harming behaviors) in the past year based on C-SSRS assessment ("yes" answers on items 4 or 5 of the C-SSRS).

- Any previous history of suicide behaviors reported or documented within the past 10 years.
- For events that occurred within the past 5 years, an answer of “yes” to any of the suicidal behavior items of the C-SSRS).
- Investigator’s judgment.

If any of these criteria are met and the participant is being considered for study participation, a risk assessment must be completed to determine whether it is appropriate for the participant to be enrolled.

Risk assessments should be done by a qualified mental health professional (MHP). In the US, a qualified MHP is a psychiatrist or a licensed PhD level clinical psychologist. In other countries a qualified MHP is a clinically-qualified professional with appropriate training in the assessment of suicide risk (according to the local clinical practice standards and regulations) and who would normally evaluate the risk for suicide for a participant.

The MHP may be a member of the study site team. If an MHP is not available within the study team, the Investigator should make the necessary referral.

The Investigator must obtain and review the risk assessment prior to the participant being randomized. A written copy of the risk assessment should be included in the participant’s clinical record (source documentation).

#### **8.2.6.3. Risk Assessment During the Study**

Beginning with Period 1, if there are any “yes” responses on items 4, 5 or on any behavioral question of the C-SSRS (since last visit), a risk assessment should be done by a qualified MHP to determine whether it is safe for the participant to continue to participate in the trial. Suicidal risk should be managed appropriately by the Investigator together with a qualified MHP (or the Investigator alone if the Investigator is a qualified MHP). In addition, the Investigator should consult with the Sponsor medical monitor to determine whether the participant can continue in the trial.

A narrative should be prepared for participants who have undergone any post-baseline risk assessment, using information from the C-SSRS.

#### **8.2.7. Pregnancy Testing**

Pregnancy tests may be urine or serum tests, but must have a sensitivity of at least 25 mIU/mL. Pregnancy tests will be performed in women of childbearing potential (WOCBP) at the times listed in the [Schedule of Activities \(SoA\)](#). Following a negative pregnancy test result at screening, appropriate contraception must be commenced, and a second negative pregnancy test result will be required at the baseline visit prior the participant’s receiving the study treatment. Pregnancy tests will also be done whenever 1 menstrual cycle is missed during the active treatment period (or when potential pregnancy is otherwise suspected) and at the end of the study. Pregnancy tests may also be repeated if requested by institutional review boards (IRBs)/ethics committees (ECs) or if required by

local regulations. If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded if the serum pregnancy result is positive.

### **8.3. Adverse Events and Serious Adverse Events**

The definitions of an AE and an SAE can be found in [Appendix 3](#).

AEs will be reported by the participant (or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized representative).

The investigator and any qualified designees are responsible for detecting, documenting, and recording events that meet the definition of an AE or SAE and remain responsible to pursue and obtain adequate information both to determine the outcome and to assess whether it meets the criteria for classification as an SAE or that caused the participant to discontinue the study (see [Section 7](#)).

In addition, the investigator may be requested by Pfizer Safety to obtain specific follow-up information in an expedited fashion.

#### **8.3.1. Time Period and Frequency for Collecting AE and SAE Information**

The time period for actively eliciting and collecting AEs and SAEs ("active collection period") for each participant begins from the time the participant provides informed consent, which is obtained before the participant's participation in the study (ie, before undergoing any study-related procedure and/or receiving investigational product), through and including a minimum of 28 calendar days, except as indicated below, after the last administration of the investigational product.

For participants who are screen failures, the active collection period ends when screen failure status is determined.

Medical occurrences that begin before the start of study intervention but after obtaining informed consent will be recorded on the Medical History/Current Medical Conditions section of the CRF, not the AE section.

Follow-up by the investigator continues throughout and after the active collection period and until the event or its sequelae resolve or stabilize at a level acceptable to the investigator, and Pfizer concurs with that assessment.

Investigators are not obligated to actively seek AE or SAE after conclusion of the study participation. However, if the investigator learns of any SAE, including a death, at any time after a participant has been discharged from the study, and he/she considers the event to be reasonably related to the study intervention or study participation, the investigator must promptly notify the sponsor.

#### **8.3.1.1. Reporting SAEs to Pfizer Safety**

All SAEs occurring in a participant during the active collection period are reported to Pfizer Safety on the CT SAE Report Form immediately and under no circumstance should this exceed 24 hours, as indicated in [Appendix 3](#). The investigator will submit any updated SAE data to the sponsor within 24 hours of it being available.

SAEs occurring in a participant after the active collection period has ended are reported to Pfizer Safety if the investigator becomes aware of them; at a minimum, all SAEs that the investigator believes have at least a reasonable possibility of being related to investigational product must be reported to Pfizer Safety.

#### **8.3.1.2. Recording Non-serious AEs and SAEs on the CRF**

During the active collection period, both non-serious AEs and SAEs are recorded on the CRF.

#### **8.3.2. Method of Detecting AEs and SAEs**

The method of recording, evaluating, and assessing causality of AEs and SAEs and the procedures for completing and transmitting SAE reports are provided in [Appendix 3](#).

Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and nonleading verbal questioning of the participant is the preferred method to inquire about AE occurrences.

#### **8.3.3. Follow-up of AEs and SAEs**

After the initial AE/SAE report, the investigator is required to proactively follow each participant at subsequent visits/contacts. For each event, the investigator must pursue and obtain adequate information until resolution, stabilization, the event is otherwise explained, or the participant is lost to follow-up (as defined in [Section 7.3](#)).

In general, follow-up information will include a description of the event in sufficient detail to allow for a complete medical assessment of the case and independent determination of possible causality. Any information relevant to the event, such as concomitant medications and illnesses, must be provided. In the case of a participant death, a summary of available autopsy findings must be submitted as soon as possible to Pfizer Safety.

Further information on follow-up procedures is given in [Appendix 3](#).

#### **8.3.4. Regulatory Reporting Requirements for SAEs**

Prompt notification by the investigator to the sponsor of an SAE is essential so that legal obligations and ethical responsibilities towards the safety of participants and the safety of a study intervention under clinical investigation are met.

The sponsor has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safety of a study intervention under clinical investigation. The sponsor will comply with country-specific regulatory requirements relating to safety

reporting to the regulatory authority, institutional review boards (IRBs)/ethics committees (ECs), and investigators.

Investigator safety reports must be prepared for suspected unexpected serious adverse reactions (SUSARs) according to local regulatory requirements and sponsor policy and forwarded to investigators as necessary.

An investigator who receives an investigator safety report describing an SAE or other specific safety information (eg, summary or listing of SAEs) from the sponsor will review and then file it along with the SRSD for the study and will notify the IRB/EC, if appropriate according to local requirements.

### **8.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational Exposure**

Exposure to the investigational product under study during pregnancy or breastfeeding and occupational exposure are reportable to Pfizer Safety within 24 hours of investigator awareness.

#### **8.3.5.1. Exposure During Pregnancy**

Details of all pregnancies in female participants and, if indicated, female partners of male participants will be collected after the start of study intervention and until 28 calendar days, after the last administration of the investigational product.

If a pregnancy is reported, the investigator should inform the sponsor within 24 hours of learning of the pregnancy and should follow the procedures outlined in [Appendix 4](#).

Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) are considered SAEs.

#### **8.3.5.2. Exposure During Breastfeeding**

Scenarios of exposure during breastfeeding must be reported, irrespective of the presence of an associated SAE, to Pfizer Safety within 24 hours of the investigator's awareness, using the CT SAE Report Form. An exposure during breastfeeding report is not created when a Pfizer drug specifically approved for use in breastfeeding women (eg, vitamins) is administered in accord with authorized use. However, if the infant experiences an SAE associated with such a drug's administration, the SAE is reported together with the exposure during breastfeeding.

#### **8.3.5.3. Occupational Exposure**

An occupational exposure occurs when, during the performance of job duties, a person (whether a healthcare professional or otherwise) gets in unplanned direct contact with the product, which may or may not lead to the occurrence of an AE.

An occupational exposure is reported to Pfizer Safety within 24 hours of the investigator's awareness, using the CT SAE Report Form, regardless of whether there is an associated SAE. Since the information does not pertain to a participant enrolled in the study, the



information is not recorded on a CRF; however, a copy of the completed CT SAE Report Form is maintained in the investigator site file.

### 8.3.6. Medication Errors

Medication errors may result from the administration or consumption of the investigational product by the wrong participant, or at the wrong time, or at the wrong dosage strength.

Exposures to the investigational product under study may occur in clinical trial settings, such as medication errors.

Safety Event	Recorded on the CRF	Reported on the CT SAE Report Form to Pfizer Safety Within 24 Hours of Awareness
Medication errors	All (regardless of whether associated with an AE)	Only if associated with an SAE

Medication errors include:

- Medication errors involving participant exposure to the investigational product;
- Potential medication errors or uses outside of what is foreseen in the protocol that do or do not involve the study participant.

Such medication errors occurring to a study participant are to be captured on the medication error page of the CRF, which is a specific version of the AE page.

In the event of a medication dosing error, the sponsor should be notified immediately.

Whether or not the medication error is accompanied by an AE, as determined by the investigator, the medication error is recorded on the medication error page of the CRF and, if applicable, any associated AE(s), serious and non-serious, are recorded on an AE page of the CRF.

Medication errors should be reported to Pfizer Safety within 24 hours on a CT SAE Report Form **only when associated with an SAE**.

### 8.4. Treatment of Overdose

For this study, any dose of Lyrica® >450 mg or oxycodone HCl >20 mg within a 24-hour time period will be considered an overdose.

Sponsor does not recommend specific treatment for an overdose.

In the event of an overdose, the investigator should:

1. Contact the medical monitor immediately.

2. Closely monitor the participant for any AEs/SAEs and laboratory abnormalities until pregabalin and oxycodone can no longer be detected systemically (at least 3 days).
3. Obtain a blood sample for PK analysis within 3 days from the date of the last dose of study intervention if requested by the medical monitor (determined on a case-by-case basis).
4. Document the quantity of the excess dose as well as the duration of the overdose in the CRF.
5. Overdose is reportable to Safety **only when associated with an SAE**.

Decisions regarding dose interruptions or modifications will be made by the investigator in consultation with the medical monitor based on the clinical evaluation of the participant.

### 8.5. Pharmacokinetics

Blood samples of approximately 5 mL, to provide a total of approximately 2.1 mL of plasma volume, will be collected for measurement of plasma concentrations of pregabalin and oxycodone as specified in the [Schedule of Activities \(SoA\)](#). Instructions for the collection and handling of biological samples will be provided in the laboratory manual or by the sponsor. The actual date and time (24-hour clock time) of each sample will be recorded.

The actual times may change, but the number of samples will remain the same. All efforts will be made to obtain the samples at the exact nominal time relative to dosing. Collection of samples up to and including 10 hours after dose administration that are obtained within 10% of the nominal time (eg, within 6 minutes of a 60-minute sample) relative to dosing will not be captured as a protocol deviation, as long as the exact time of the collection is noted on the source document and data collection tool (eg, CRF). Collection of samples more than 10 hours after dose administration that are obtained  $\leq 1$  hour away from the nominal time relative to dosing will not be captured as a protocol deviation, as long as the exact time of the collection is noted on the source document and data collection tool (eg, CRF).

Samples will be used to evaluate the PK of pregabalin and oxycodone. Samples collected for analyses of pregabalin and oxycodone plasma concentration may also be used to evaluate safety or efficacy aspects related to concerns arising during or after the study, for metabolite identification and/or evaluation of the bioanalytical method, or for other internal exploratory purposes.

Genetic analyses will not be performed on these plasma samples. Participant confidentiality will be maintained.

Samples collected for measurement of plasma concentrations of pregabalin and oxycodone will be analyzed using a validated analytical method in compliance with applicable standard operating procedures (SOPs).



The PK samples must be processed and shipped as indicated in the instructions provided to the investigator site to maintain sample integrity. Any deviations from the PK sample handling procedure (eg, sample collection and processing steps, interim storage or shipping conditions), including any actions taken, must be documented and reported to the sponsor. On a case-by-case basis, the sponsor may make a determination as to whether sample integrity has been compromised.

Drug concentration information that may unblind the study will not be reported to investigator sites or blinded personnel until the study has been unblinded.

Any changes in the timing or addition of time points for any planned study assessments must be documented and approved by the relevant study team member and then archived in the sponsor and site study files, but will not constitute a protocol amendment. The IRB/EC will be informed of any safety issues that require alteration of the safety monitoring scheme or amendment of the ICD.

## **8.6. Pharmacodynamics**

### **8.6.1. Subjective Effects**

The questionnaire described below is used in drug abuse as well as clinical efficacy and toxicity evaluation of pharmacologic agents, and its usefulness is widely accepted. Furthermore, previous results indicate that the instrument is sensitive, reliable, and valid.

#### **8.6.1.1. Visual Analog Scale (VAS)**

The VAS consists of horizontal 100-mm lines, each labeled with an adjective such as “Drug Liking” or “High”, etc. Participants will be instructed to place a mark on each line indicating how they feel at the moment. For example, for “Drug Liking” the participant will be asked: At this moment, my liking for this drug is? The participant will then rate on the 0 to 100 scale, where: Strong disliking = 0; Neither like nor Dislike = 50; and Strong Liking = 100.

#### Primary Endpoints

- VAS for Drug Liking presented on a bipolar 0 to 100 scale.

#### Secondary Endpoints

- VAS for High presented on a unipolar 0 to 100 scale.
- VAS for Take Drug Again presented on a bipolar 0 to 100 scale.
- VAS for Overall Drug Liking presented on a bipolar 0 to 100 scale.
- VAS for Any Drug Effects, Good Drug Effects, and Bad Drug Effects presented on unipolar 0 to 100 scales.

## **8.7. Genetics**

### **8.7.1. Specified Genetics**

Genetics (specified analysis) are not evaluated in this study.

### **8.7.2. Banked Biospecimens for Genetics**

A 4-mL blood sample optimized for deoxyribonucleic acid (DNA) isolation Prep D1 will be collected as local regulations and IRBs/ECs allow.

Banked biospecimens may be used for research related to drug response. Genes and other analytes (eg, proteins, ribonucleic acid (RNA), nondrug metabolites) may be studied using the banked samples.

Unless prohibited by local regulations or IRB/EC decision, participants will be asked to indicate on the consent document whether they will allow their banked biospecimens to also be used to design and conduct research in order to gain a further understanding of other diseases and to advance science, including development of other medicines for patients. This component of the sampling banking is optional for participants; they may still participate in the study even if they do not agree to the additional research on their banked biospecimens. The optional additional research does not require the collection of any further samples.

See [Appendix 5](#) for information regarding genetic research. Details on processes for collection and shipment of these samples can be found in the Lab Manual.

## **8.8. Biomarkers**

Biomarkers are not evaluated in this study.

## **8.9. Health Economics**

Health economics/medical resource utilization and health economics parameters are not evaluated in this study.

## **9. STATISTICAL CONSIDERATIONS**

Detailed methodology for summary and statistical analyses of the data collected in this study is outlined here and further detailed in a statistical analysis plan (SAP), which will be maintained by the sponsor. The SAP may modify what is outlined in the protocol where appropriate; however, any major modifications of the primary endpoint definitions or their analyses will also be reflected in a protocol amendment.

The Statistical Analysis Plan will be developed and finalized before database lock and will describe the participant populations to be included in the analyses, and procedures for accounting for missing, unused, and spurious data.

## 9.1. Statistical Hypothesis

To assess the abuse potential of Lyrica® the following tests will be performed in the order of validation test followed by combination vs. oxycodone and then pregabalin alone vs. oxycodone:

Study Validation:

The sensitivity and integrity of the study will be validated by comparing the mean responses of oxycodone HCl, the positive control (C), to the placebo (P):

$$H_0: \mu_C - \mu_P \leq \delta_I \text{ versus } H_a: \mu_C - \mu_P > \delta_I \text{ where } \delta_I = 15$$

### Primary:

1. Does pregabalin plus oxycodone HCl (T) produce mean responses that show abuse potential that is no higher than oxycodone HCl (C)?

$$H_0: \mu_T - \mu_C \geq 0.2(\mu_C - \mu_P) \text{ versus } H_a: \mu_T - \mu_C < 0.2(\mu_C - \mu_P).$$

### Secondary:

1. Does pregabalin (L) produce mean responses that show less abuse potential than oxycodone HCl (C)?

$$H_0: \mu_C - \mu_L \leq 0.2(\mu_C - 50) \text{ versus } H_a: \mu_C - \mu_L > 0.2(\mu_C - 50).^{17}$$

2. Does pregabalin (L) produce mean responses that show abuse potential similar to placebo (P)?

$$H_0: \mu_L - \mu_P \geq \delta_2 \text{ versus } H_a: \mu_L - \mu_P < \delta_2 \text{ where } \delta_2 = 11.$$

3. Does pregabalin (L) produce mean responses that show less abuse potential than pregabalin plus oxycodone HCl (T)?

$$H_0: \mu_T - \mu_L \leq 0.2(\mu_T - 50) \text{ versus } H_a: \mu_T - \mu_L > 0.2(\mu_T - 50).^{17}$$

For each of the pregabalin hypothesis, the statistical significance of the test will be assessed for all doses of pregabalin.

## 9.2. Sample Size Determination

Forty two (42) participants will provide 90% power to demonstrate the difference between pregabalin plus oxycodone HCl and oxycodone HCl alone is no larger than 20% of the difference between oxycodone HCl and placebo. This assumes means (SD) of 75.0 (16), 75.0 (16), and 51.6 (6.77) for pregabalin plus oxycodone HCl, oxycodone HCl, and placebo, respectively. The correlation between pregabalin plus oxycodone HCl is assumed to be 0.85.

A 15-point VAS  $E_{\max}$  “Drug Liking” difference between the placebo and the positive control oxycodone HCl must be demonstrated for validation of the study. Thirty-six (36)

participants will provide at least 90% power to show the positive control (20 mg dose of oxycodone IR given alone) is 15 points higher than placebo. This assumes a difference of 23 points between placebo and oxycodone HCl given alone, a standard deviation of 16 points and a 1-sided significance level of 0.05 and correlation of 0 between oxycodone HCl and placebo.

The maximum number of participants needed for the primary analysis and validation of the study will provide at least 90% power for both analyses and to account for participants who will be excluded from the Modified Completer Population, 48 participants will be required to complete the study. To account for participants who do not complete all 6 treatments this study will randomize 60 participants to ensure at least 48 participants complete the Treatment Phase of the study. Among the 60 participants, at least 20% will be females to ensure that the findings are valid across different populations.

### 9.3. Populations for Analysis

The following populations are planned for this study:

- The Safety Population will include all participants who receive at least one dose of study drug, beginning with the Naloxone Challenge. This population will be analyzed as treated.
- The PK population will include all enrolled participants treated who have at least 1 concentration in the Treatment Phase. The PK parameter analysis population will include all enrolled participants treated who have at least 1 of the PK parameters of interest.
- The Completer Population will include all randomized participants who complete all 6 periods of the Treatment Phase and who contribute post-dose PD data from each period. These participants must have all post-dose responses for each treatment group present until median  $T_{max}$  sampling time after dosing.
- The Modified Completer Population will include all randomized participants in the Completer Population, however will exclude any participant who meets either or both of the following criteria for Drug Liking VAS:
  1.  $E_{max}$  scores are within a 5 point difference across all 6 treatments (ie,  $\text{Maximum } E_{max} \text{ score} - \text{Minimum } E_{max} \text{ score} \leq 5$ ).
  2.  $E_{max}(P) > 60$  and  $E_{max}(P) - E_{max}(Oxy20) \geq 5$ .

where  $E_{max}(P)$  and  $E_{max}(Oxy20)$  are the VAS  $E_{max}$  scores for placebo and oxycodone HCl IR 20 mg, respectively.

This population will be analyzed as randomized.

- The Evaluable Population will include all randomized participants in the Completer Population who do not have major protocol violations or adverse events that would interfere with drug absorption such as vomiting within 4 hours of study drug administration. Major protocol violations, including deviations related to study drug intake are defined as those that could potentially affect the PD conclusions of the study. Prior to unblinding the Treatment Phase data, the Sponsor (or designee) will identify protocol violations or adverse events that would disqualify a participant from the evaluable population and determine which participants or participant visits will be excluded. This population will be analyzed as randomized.

All PD analyses will be performed using the Modified Completer Population and all available postdose data; these will be the primary PD analyses. Key PD analyses may be repeated on the Evaluable Population using all available post-dose data.

#### **9.4. Statistical Analysis**

Statistically, the study will be evaluated as a safety study. Consequently, the null hypothesis for pregabalin alone and when used concomitantly with oxycodone HCl will be constructed on the presumption that these treatments produce abuse potential similar to oxycodone HCl and therefore differentiates from placebo. To demonstrate that these treatments have no abuse potential the null hypothesis will be statistically rejected.

The SAP will be developed and finalized before database lock and will describe the participant populations to be included in the analyses, and procedures for accounting for missing, unused, and spurious data. This section is a summary of the planned statistical analyses of the primary and secondary endpoints.

##### **9.4.1. Endpoint Analysis**

The following parameters will be calculated for VAS for “Drug Liking” and VAS for “High” during the Treatment Period:

- Maximum (peak) effect ( $E_{\max}$ ) for High only; calculated as maximum change from pre-dose response if pre-dose assessment is performed;
- Time of maximum (peak) effect ( $TE_{\max}$ );
- Area under the effect curve to 1 hour ( $AUEC_1$ );
- Area under the effect curve to 2 hour ( $AUEC_2$ );
- Area under the effect curve to 3 hour ( $AUEC_3$ );
- Area under the effect curve to 4 hour ( $AUEC_4$ );
- Area under the effect curve to 8 hour ( $AUEC_8$ );
- $AUEC_{\text{last}}$ .

The VAS for “Overall Drug Liking”, “Take Drug Again”, “Good Drug Effect”, “Bad Drug Effect”, and “Ang Drug Effect” will be summarized by timepoints.

#### 9.4.2. Study Validity of Analysis of Endpoints

Study validity will first be confirmed through the comparison of mean  $E_{\max}$  for Drug Liking between oxycodone and placebo administered during the Treatment Phase. This comparison will be made using a mixed-effect model with treatment, period, treatment\*period interaction, a carryover variable and sequence as fixed effects, and participant nested within sequence as a random effect. If the p-value for the carryover variable is  $>0.25$ , a reduced mixed model will be used with treatment, period and sequence as fixed effects, and participant nested within sequence as a random effect. If the treatment comparison of oxycodone vs. placebo is statistically significant (ie, one-sided  $p \leq 0.05$ ) in the appropriate direction and confidence intervals exclude differences of  $<15$  points for Drug Liking, it will confirm the sensitivity of the study. If study validity is not confirmed, comparisons between pregabalin and oxycodone will not be performed.

#### 9.4.3. Analysis of Primary and Secondary Endpoints

A linear mixed-effects model with treatment, period, treatment\*period interaction, a carryover variable and sequence as fixed effects, and participant nested within sequence as a random effect. If the p-value for the carryover variable is  $>0.25$ , a reduced mixed model will be used with treatment, period and sequence as fixed effects, and participant nested within sequence as a random effect. The primary analyses of abuse potential will be based on testing the differences between the means from the primary measure(s) at the peak of drug response effects (VAS  $E_{\max}$ ) produced by pregabalin, oxycodone HCl and placebo at a significance level of 0.05 (1-sided).

The primary PD endpoint is the  $E_{\max}$  of bipolar VAS for “Drug Liking”.

The principal parameters for the primary and secondary endpoints will be summarized by treatment using descriptive statistics (mean, standard error [SE], median, first and third quartiles, minimum and maximum). These parameters will be analyzed using a mixed-effect model with treatment, period, treatment\*period interaction, a carryover variable and sequence as fixed effects, and participant nested within sequence as a random effect. If the p-value for the carryover variable is  $>0.25$ , a reduced mixed model will be used with treatment, period and sequence as fixed effects, and participant nested within sequence as a random effect. Analyses of endpoints with baseline (pre-dose) measurements will include the baseline measurement as a covariate in the model. Least squares means, standard errors, and one-sided 95% confidence intervals will be provided for each treatment and for the difference between treatments. P-values will be provided for each hypothesis. A two-sided 95% confidence interval will be provided for the comparisons of pregabalin (300 mg and 450 mg) plus oxycodone versus oxycodone IR 20 mg. Data will be summarized graphically, where appropriate.

The study validation comparisons will be:

- Oxycodone HCl IR 20 mg vs. placebo.

The primary treatment comparisons will be:

- Pregabalin 300 mg plus oxycodone HCl IR 20 mg vs. oxycodone HCl IR 20 mg;
- Pregabalin 450 mg plus oxycodone HCl IR 20 mg vs. oxycodone HCl IR 20 mg.

The secondary treatment comparisons will be:

- Pregabalin 300 mg vs. placebo;
- Pregabalin 450 mg vs. placebo;
- Pregabalin 300 mg plus oxycodone HCl IR 20 mg vs. placebo;
- Pregabalin 450 mg plus oxycodone HCl IR 20 mg vs. placebo;
- Pregabalin 300 mg vs. oxycodone HCl IR 20 mg;
- Pregabalin 450 mg vs. oxycodone HCl IR 20 mg;
- Pregabalin 300 mg plus oxycodone HCl IR 20 mg vs. pregabalin 300 mg;
- Pregabalin 450 mg plus oxycodone HCl IR 20 mg vs. pregabalin 450 mg.

Statistical significance of all treatment differences will be reported. All statistical tests will be conducted using one tailed significance criteria. These comparisons will be used to assess the primary study objective.

Regression diagnostics will be performed to verify model assumptions and adequacy of the fitted linear models for the primary endpoints. Levene's test will be used to diagnose potential heterogeneity of variance and the Shapiro-Wilk test will be used to diagnose potential non-normality of the model residuals.

If the resulting p-value from Levene's test is  $\leq 0.05$ , the null hypothesis of equal variances is rejected and it will be concluded that there is a difference between the treatment group variances. An unequal variance model will then be applied using the Satterthwaite method in order to produce an accurate F-approximation.

If the resulting p-value from the Shapiro-Wilk test is  $\leq 0.05$ , symmetry of the distribution of paired differences will be tested using the Triples Test and either the t test (symmetry) or sign test (asymmetry) will be performed.

#### **9.4.3.1. Pharmacodynamic Analysis**

Pharmacodynamic parameter values that will be evaluated are listed in Table 4. The pre-dose measurements of psychometric and pupillometry of each period will be the



baseline for calculating the changes in these parameters post dose. Descriptive statistics for the changes from baseline will be reported by treatment and by hours postdose. The changes from baseline will be analyzed with an analysis of covariance (ANOVA) model consisting of: Sequence, Period, Treatment, Time, Period\*Time and Treatment\*Time terms as fixed effects, and a participant (Sequence) term as a random effect. To accommodate the repeated measures aspect of the design, a compound symmetric covariance matrix will be employed, with the participant set to Period\*Participant (Sequence). The Treatment\*Time least-squares means and differences among them will be assessed for trends likely to be of clinical relevance.

Descriptive statistics of the mean, standard error, and other summary statistics such as minimum, first quartile (Q1), median, third quartile (Q3) and maximum for each subjective measure, each treatment and each paired difference among treatments will be calculated and used to create tables and graphs.

Pupil size will be summarized by time points.

As an exploratory analysis, the time course of the different subjective measures in relation to each other (and to abuse-related AEs) will evaluate the outcome of positive or negative assessments of the drug before, during and after the peak of drug effects. The physiological effects such as pulse rate, blood pressure, respiratory rate and pupil size will be monitored over the course of the study session and correlated to both the drug dose administered and the PK of the drug.

#### 9.4.3.1.1. Derivation of Pharmacodynamic Parameters

PD parameters for VAS “Drug Liking” and “High” will be derived from the effect-time profiles as shown in Table 4.

**Table 4. Derivation of Pharmacodynamic Parameters**

Parameter	Definition	Method of Determination
E <sub>max</sub>	Maximum effect	Observed directly from data
TE <sub>max</sub>	Time for E <sub>max</sub>	Observed directly from data as time of first occurrence
AUEC <sub>last</sub>	Area under the effect-time profile from time zero to the time of the last quantifiable effect (C <sub>last</sub> )	Linear trapezoidal method
AUEC <sub>1</sub>	Area under the effect-time profile from time zero to 1 hour postdose	Linear trapezoidal method
AUEC <sub>2</sub>	Area under the effect-time profile from time zero to 2 hour postdose	Linear trapezoidal method
AUEC <sub>3</sub>	Area under the effect-time profile from time zero to 3 hour postdose	Linear trapezoidal method
AUEC <sub>4</sub>	Area under the effect-time profile from time zero to 4 hour postdose	Linear trapezoidal method
AUEC <sub>8</sub>	Area under the effect-time profile from time zero to 8 hour postdose	Linear trapezoidal method



### 9.4.3.2. Pharmacokinetic Analysis

Blood samples will be collected throughout the study in order to monitor drug PK. This will be done to primarily confirm that plasma levels of the drug are equivalent between participants and to evaluate whether subjective measures and AEs can be correlated with drug levels over time. Typically, blood will be drawn immediately after the collection of subjective measures are completed at each time point. If an analysis shows that a participant had low plasma levels of a drug, it may account for a lack of subjective responses in a drug session.

#### 9.4.3.2.1. Pharmacokinetic Parameters

The following pregabalin and oxycodone PK parameters (Table 5) will be calculated for each participant/period/analyte using noncompartmental analysis of concentration-time data. Samples below the LLOQ were set to 0 for analysis. Actual sample collection times were used for the PK analysis.

The PK parameters ( $AUC_{inf}$ ,  $AUC_{last}$ ,  $C_{max}$ ,  $T_{max}$ ,  $t_{1/2}$ , partial AUCs [ $AUC_1$ ,  $AUC_2$ ,  $AUC_3$ ,  $AUC_4$ ,  $AUC_8$ ]) will be derived for each participant/period/analyte and will be summarized by treatment and analyte. Individual participant PK parameters, as well as summary statistics (eg, group averages, standard deviation [SD], geometric means, coefficient of variation [CV] and geometric CV%) by treatment will be reported for PK parameters, as appropriate. Plasma concentration-time profiles of pregabalin and oxycodone will be presented. Concentrations will be listed and summarized by PK sampling time and treatment for each analyte.

**Table 5. Pharmacokinetic Parameters**

Parameter	Definition	Method of Determination
$C_{max}$	Maximum plasma concentration	Observed directly from data
$T_{max}$	Time for $C_{max}$	Observed directly from data as time of first occurrence
$AUC_{last}$	Area under plasma concentration-time profile from time zero to the time for the last quantifiable concentration ( $C_{last}$ )	Linear/Log trapezoidal method
$AUC_1$	Area under plasma concentration-time profile from time zero to 1 hour postdose	Linear/Log trapezoidal method
$AUC_2$	Area under plasma concentration-time profile from time zero to 2 hour postdose	Linear/Log trapezoidal method
$AUC_3$	Area under plasma concentration-time profile from time zero to 3 hour postdose	Linear/Log trapezoidal method
$AUC_4$	Area under plasma concentration-time profile from time zero to 4 hour postdose	Linear/Log trapezoidal method
$AUC_8$	Area under plasma concentration-time profile from time zero to 8 hour postdose	Linear/Log trapezoidal method
$AUC_{inf}^a$	Area under plasma concentration-time profile	$AUC_{lastC0} + (C_{last}^*/k_{el})$ , where $C_{last}^*$ is the predicted plasma

Parameter	Definition	Method of Determination
	from time zero to infinity postdose	concentration at the last quantifiable time point estimated from the log-linear regression analysis
$t_{1/2}^a$	Terminal half-life	$\ln(2)/k_{el}$ , where $k_{el}$ is the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline will be used in the regression

a. If data permit.

#### 9.4.4. Efficacy Analyses

There will not be an efficacy analysis in this study.

#### 9.4.5. Safety Analyses

All safety analyses will be performed on the safety population.

The safety data will be described and summarized in accordance with the sponsor's Data Standards.

AEs, ECGs, BP, RR, PR, SpO<sub>2</sub>, continuous cardiac monitoring, and safety laboratory data will be reviewed and summarized on an ongoing basis during the study to evaluate the safety of participants. Any clinical laboratory, ECG, BP, and pulse rate abnormalities of potential clinical concern will be described. Safety data will be presented in tabular and/or graphical format and summarized descriptively, where appropriate.

Medical history and physical examination and neurological examination information, as applicable, collected during the course of the study will be considered source data and will not be required to be reported, unless otherwise noted. However, any untoward findings identified on physical and/or neurological examinations conducted during the active collection period will be captured as AEs, if those findings meet the definition of an AE. Data collected at screening that are used for inclusion/exclusion criteria, such as laboratory data, ECGs, and vital signs, will be considered source data, and will not be required to be reported, unless otherwise noted. Demographic data collected at screening will be reported.

##### 9.4.5.1. Electrocardiogram Analyses

Electrocardiogram results collected at Screening will be listed.

#### **9.4.6. Exploratory Analyses**

Exploratory analysis will be conducted to evaluate the correlation between pregabalin concentrations and selected PD endpoints (Bipolar VAS for “Drug Liking”, Unipolar VAS for “High”, pupil diameter) in the presence and absence of oxycodone, as data permit.

#### **9.5. Interim Analyses**

No formal interim analysis will be conducted for this study.

#### **9.6. Data Monitoring Committee**

This study will not use a data monitoring committee (DMC).

## **10. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS**

### **10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations**

#### **10.1.1. Regulatory and Ethical Considerations**

This study will be conducted in accordance with the protocol and with the following:

- Consensus ethical principles derived from international guidelines including the Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines;
- Applicable International Council for Harmonisation (ICH) Good Clinical Practice (GCP) guidelines;
- Applicable laws and regulations, including applicable privacy laws.

The protocol, protocol amendments, ICD, investigator's brochure (IB), and other relevant documents (eg, advertisements) must be reviewed and approved by the sponsor and submitted to an IRB/EC by the investigator and reviewed and approved by the IRB/EC before the study is initiated.

Any amendments to the protocol will require IRB/EC approval before implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study participants.

The investigator will be responsible for the following:

- Providing written summaries of the status of the study to the IRB/EC annually or more frequently in accordance with the requirements, policies, and procedures established by the IRB/EC;
- Notifying the IRB/EC of SAEs or other significant safety findings as required by IRB/EC procedures;
- Providing oversight of the conduct of the study at the site and adherence to requirements of 21 Code of Federal Regulations (CFR), ICH guidelines, the IRB/EC, European regulation 536/2014 for clinical studies (if applicable), and all other applicable local regulations.

##### **10.1.1.1. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP**

In the event of any prohibition or restriction imposed (ie, clinical hold) by an applicable regulatory authority in any area of the world, or if the investigator is aware of any new information that might influence the evaluation of the benefits and risks of the investigational product, sponsor should be informed immediately.

In addition, the investigator will inform sponsor immediately of any urgent safety measures taken by the investigator to protect the study participants against any immediate hazard, and

of any serious breaches of this protocol or of ICH GCP that the investigator becomes aware of.

#### **10.1.2. Financial Disclosure**

Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial information as requested to allow the sponsor to submit complete and accurate financial certification or disclosure statements to the appropriate regulatory authorities. Investigators are responsible for providing information on financial interests during the course of the study and for 1 year after completion of the study.

#### **10.1.3. Informed Consent Process**

The investigator or his/her representative will explain the nature of the study to the participant and answer all questions regarding the study.

Participants must be informed that their participation is voluntary. Participants will be required to sign a statement of informed consent that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, Health Insurance Portability and Accountability Act (HIPAA) requirements, where applicable, and the IRB/EC or study center.

The investigator must ensure that each study participant is fully informed about the nature and objectives of the study, the sharing of data related to the study, and possible risks associated with participation, including the risks associated with the processing of the participant's personal data.

The participant must be informed that his/her personal study-related data will be used by the sponsor in accordance with local data protection law. The level of disclosure must also be explained to the participant.

The participant must be informed that his/her medical records may be examined by Clinical Quality Assurance auditors or other authorized personnel appointed by the sponsor, by appropriate IRB/EC members, and by inspectors from regulatory authorities.

The investigator further must ensure that each study participant is fully informed about his or her right to access and correct his or her personal data and to withdraw consent for the processing of his or her personal data.

The medical record must include a statement that written informed consent was obtained before the participant was enrolled in the study and the date the written consent was obtained. The authorized person obtaining the informed consent must also sign the ICD.

Participants must be reconsented to the most current version of the ICD(s) during their participation in the study.

A copy of the ICD(s) must be provided to the participant.

A participant who is rescreened is not required to sign another ICD if the rescreening occurs within 28 days from the previous ICD signature date.

#### **10.1.4. Data Protection**

All parties will comply with all applicable laws, including laws regarding the implementation of organizational and technical measures to ensure protection of participant data.

Participants' personal data will be stored at the study site in encrypted electronic form and/or paper and will be password protected or secured in a locked room to ensure that only authorized study staff have access. The study site will implement appropriate technical and organizational measures to ensure that the personal data can be recovered in the event of disaster. In the event of a potential personal data breach, the study site shall be responsible for determining whether a personal data breach has in fact occurred and, if so, providing breach notifications as required by law.

To protect the rights and freedoms of natural persons with regard to the processing of personal data, participants will be assigned a single, participant-specific numerical code. Any participant records or data sets that are transferred to the sponsor will contain the numerical code; participant names will not be transferred. All other identifiable data transferred to the sponsor will be identified by this single, participant-specific code. The study site will maintain a confidential list of participants who participated in the study, linking each participant's numerical code to his or her actual identity. In case of data transfer, the sponsor will protect the confidentiality of participants' personal data consistent with the clinical study agreement and applicable privacy laws.

#### **10.1.5. Dissemination of Clinical Study Data**

Upjohn fulfills its commitment to publicly disclose clinical study results through posting the results of studies on [www.clinicaltrials.gov](http://www.clinicaltrials.gov) (ClinicalTrials.gov), the European Clinical Trials Database (EudraCT), and other public registries in accordance with applicable local laws/regulations. In addition, Upjohn reports study results outside of the requirements of local laws/regulations pursuant to its standard operating procedures (SOPs).

In all cases, study results are reported by Upjohn in an objective, accurate, balanced, and complete manner and are reported regardless of the outcome of the study or the country in which the study was conducted.

[www.clinicaltrials.gov](http://www.clinicaltrials.gov)

Upjohn posts clinical trial US Basic Results on [www.clinicaltrials.gov](http://www.clinicaltrials.gov) for Upjohn-sponsored interventional studies (conducted in patients) that evaluate the safety and/or efficacy of a product, regardless of the geographical location in which the study is conducted.

[EudraCT](#)

Upjohn posts European Union (EU) Basic Results on EudraCT for all Upjohn-sponsored interventional studies that are in scope of EU requirements. EU Basic Results are submitted

for posting within 1 year of the PCD for studies in adult populations or within 6 months of the PCD for studies in pediatric populations.

#### Documents within marketing authorization packages/submissions

Upjohn complies with the European Union Policy 0070, the proactive publication of clinical data to the European Medicines Agency (EMA) website. Clinical data, under Phase 1 of this policy, includes clinical overviews, clinical summaries, CSRs, and appendices containing the protocol and protocol amendments, sample CRFs, and statistical methods. Clinical data, under Phase 2 of this policy, includes the publishing of individual participant data. Policy 0070 applies to new marketing authorization applications submitted via the centralized procedure since 01 January 2015 and applications for line extensions and for new indications submitted via the centralized procedure since 01 July 2015.

#### Data Sharing

Upjohn provides researchers secure access to patient-level data or full CSRs for the purposes of “bona-fide scientific research” that contribute to the scientific understanding of the disease, target, or compound class. Upjohn will make available data from these trials 24 months after study completion. Patient-level data will be anonymized in accordance with applicable privacy laws and regulations. CSRs will have personally identifiable information redacted.

Data requests are considered from qualified researchers with the appropriate competencies to perform the proposed analyses. Research teams must include a biostatistician. Data will not be provided to applicants with significant conflicts of interest, including individuals requesting access for commercial/competitive or legal purposes.

##### **10.1.6. Data Quality Assurance**

All participant data relating to the study will be recorded on printed or electronic CRF unless transmitted to the sponsor or designee electronically (eg, laboratory data). The investigator is responsible for verifying that data entries are accurate and correct by physically or electronically signing the CRF.

The investigator must maintain accurate documentation (source data) that supports the information entered in the CRF.

The investigator must ensure that the CRFs are securely stored at the study site in encrypted electronic and/or paper form and are password protected or secured in a locked room to prevent access by unauthorized third parties.

The investigator must permit study-related monitoring, audits, IRB/EC review, and regulatory agency inspections and provide direct access to source data documents. This verification may also occur after study completion. It is important that the investigator(s) and their relevant personnel are available during the monitoring visits and possible audits or inspections and that sufficient time is devoted to the process.



Monitoring details describing strategy (eg, risk-based initiatives in operations and quality such as risk management and mitigation strategies and analytical risk-based monitoring), methods, responsibilities, and requirements, including handling of noncompliance issues and monitoring techniques (central, remote, or on-site monitoring), are provided in the monitoring plan.

The sponsor or designee is responsible for the data management of this study, including quality checking of the data.

Study monitors will perform ongoing source data verification to confirm that data entered into the CRF by authorized site personnel are accurate, complete, and verifiable from source documents; that the safety and rights of participants are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements.

Records and documents, including signed ICDs, pertaining to the conduct of this study must be retained by the investigator for 15 years after study completion unless local regulations or institutional policies require a longer retention period. No records may be destroyed during the retention period without the written approval of the sponsor. No records may be transferred to another location or party without written notification to the sponsor. The investigator must ensure that the records continue to be stored securely for as long as they are maintained.

When participant data are to be deleted, the investigator will ensure that all copies of such data are promptly and irrevocably deleted from all systems.

The investigator(s) will notify the sponsor or its agents immediately of any regulatory inspection notification in relation to the study. Furthermore, the investigator will cooperate with the sponsor or its agents to prepare the investigator site for the inspection and will allow the sponsor or its agent, whenever feasible, to be present during the inspection. The investigator site and investigator will promptly resolve any discrepancies that are identified between the study data and the participant's medical records. The investigator will promptly provide copies of the inspection findings to the sponsor or its agent. Before response submission to the regulatory authorities, the investigator will provide the sponsor or its agents with an opportunity to review and comment on responses to any such findings.

#### **10.1.7. Source Documents**

Source documents provide evidence for the existence of the participant and substantiate the integrity of the data collected. Source documents are filed at the investigator site.

Data reported on the CRF or entered in the electronic CRF (eCRF) that are transcribed from source documents must be consistent with the source documents or the discrepancies must be explained. The investigator may need to request previous medical records or transfer records, depending on the study. Also, current medical records must be available.

Definition of what constitutes source data can be found in the Clinical Monitoring Plan.



#### **10.1.8. Study and Site Closure**

The sponsor designee reserves the right to close the study site or terminate the study at any time for any reason at the sole discretion of the sponsor. Study sites will be closed upon study completion. A study site is considered closed when all required documents and study supplies have been collected and a study-site closure visit has been performed.

The investigator may initiate study-site closure at any time upon notification to the sponsor if requested to do so by the responsible IRB/EC or if such termination is required to protect the health of study participants.

Reasons for the early closure of a study site by the sponsor may include but are not limited to:

- Failure of the investigator to comply with the protocol, the requirements of the IRB/EC or local health authorities, the sponsor's procedures, or GCP guidelines;
- Inadequate recruitment of participants by the investigator;
- Discontinuation of further study intervention development.

Study termination is also provided for in the clinical study agreement. If there is any conflict between the contract and this protocol, the contract will control as to termination rights.

#### **10.1.9. Publication Policy**

The results of this study may be published or presented at scientific meetings by the investigator after publication of the overall study results or 1 year after end of the study (or study termination), whichever comes first.

The investigator agrees to refer to the primary publication in any subsequent publications such as secondary manuscripts, and submits all manuscripts or abstracts to the sponsor 30 days before submission. This allows the sponsor to protect proprietary information and to provide comments and the investigator will, on request, remove any previously undisclosed confidential information before disclosure, except for any study- or Upjohn-intervention related information necessary for the appropriate scientific presentation or understanding of the study results.

For all publications relating to the study, the investigator will comply with recognized ethical standards concerning publications and authorship, including those established by the International Committee of Medical Journal Editors.

The sponsor will comply with the requirements for publication of the overall study results covering all investigator sites. In accordance with standard editorial and ethical practice, the sponsor will support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement.

Authorship of publications for the overall study results will be determined by agreement and in line with International Committee of Medical Journal Editors authorship requirements.

If publication is addressed in the clinical study agreement, the publication policy set out in this section will not apply.

#### **10.1.10. Sponsor's Qualified Medical Personnel**

The contact information for the sponsor's appropriately qualified medical personnel for the study is documented in the study contact list located in the team SharePoint site.

To facilitate access to appropriately qualified medical personnel on study-related medical questions or problems, participants are provided with a contact card. The contact card contains, at a minimum, protocol and investigational product identifiers, participant numbers, contact information for the investigator site, and contact details for a contact center in the event that the investigator site staff cannot be reached to provide advice on a medical question or problem originating from another healthcare professional not involved in the participant's participation in the study. The contact number can also be used by investigator staff if they are seeking advice on medical questions or problems; however, it should be used only in the event that the established communication pathways between the investigator site and the study team are not available. It is therefore intended to augment, but not replace, the established communication pathways between the investigator site and the study team for advice on medical questions or problems that may arise during the study.

## 10.2. Appendix 2: Clinical Laboratory Tests

The following safety laboratory tests (Table 6) will be performed at times defined in the [Schedule of Activities \(SoA\)](#) section of this protocol. Additional laboratory results may be reported on these samples as a result of the method of analysis or the type of analyzer used by the clinical laboratory; or as derived from calculated values. These additional tests would not require additional collection of blood. Unscheduled clinical laboratory measurements may be obtained at any time during the study to assess any perceived safety concerns.

**Table 6. Laboratory Tests**

Hematology	Chemistry	Urinalysis	Other
Hemoglobin	BUN/urea and creatinine	pH	FSH <sup>b</sup>
Hematocrit	Glucose (fasting)	Glucose (qual)	Urine drug screening <sup>c</sup>
RBC count	Calcium	Protein (qual)	Alcohol breathalyzer or
MCV	Sodium	Blood (qual)	urine
MCH	Potassium	Ketones	β-hCG <sup>d</sup>
MCHC	Chloride	Nitrites	Hepatitis B surface
Platelet count	Total CO <sub>2</sub> (bicarbonate)	Leukocyte esterase	antigen
WBC count	AST, ALT	Urobilinogen	Hepatitis B core
Total neutrophils (Abs)	Total bilirubin	Urine bilirubin	antibody
Eosinophils (Abs)	Alkaline phosphatase	Microscopy <sup>a</sup>	Hepatitis C core
Monocytes (Abs)	Uric acid		antibody
Basophils (Abs)	Albumin		Human
Lymphocytes (Abs)	Total protein		immunodeficiency virus
	Additional Tests		HAV IgM
	(Needed for Hy's Law)		HAV IgG
	AST, ALT (repeat)		
	Total bilirubin (repeat)		
	Albumin (repeat)		
	Alkaline phosphatase		
	(repeat)		
	Direct bilirubin		
	Indirect bilirubin		
	Creatine kinase		
	GGT		
	PT/INR		
	Total bile acids		
	Acetaminophen drug		
	and/or protein adduct		
	levels		

Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; β-hCG = beta human chorionic gonadotropin; BUN = blood urea nitrogen; FSH = follicle stimulating hormone; GGT = gamma glutamyl transferase; HAV IgG = hepatitis A virus immunoglobulin G; HAV IgM = hepatitis A virus immunoglobulin M; INR = international normalized ratio; MCH = mean corpuscular hemoglobin; MCHC = mean corpuscular hemoglobin concentration; MCV = mean corpuscular volume; PT = prothrombin time; RBC = red blood cell; WBC = white blood cell.

- Only if urine dipstick is positive for blood, protein, nitrites or leukocyte esterase.
- For confirmation of postmenopausal status only.
- The minimum requirement for drug screening includes cocaine, tetrahydrocannabinol (THC), opiates/opioids, benzodiazepines, and amphetamines (others are site and study specific).
- Serum or urine β-hCG for female participants of childbearing potential.

Investigators must document their review of each laboratory safety report.

Laboratory/analyte results that could unblind the study will not be reported to investigator sites or other blinded personnel until the study has been unblinded.

Any remaining serum/plasma from samples collected for clinical safety laboratory measurements at baseline and at all times after dose administration may be retained and stored for the duration of the study. Upon completion of the study, these retained safety samples may be used for the assessment of exploratory safety biomarkers or unexpected safety findings. These data will not be included in the CSR. Samples to be used for this purpose will be shipped to either a Upjohn-approved Biospecimen Banking System (BBS) facility or other designated laboratory and retained for up to 1 year following the completion of the study.

### **10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting**

#### **10.3.1. Definition of AE**

<b>AE Definition</b>
<ul style="list-style-type: none"><li>• An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</li><li>• NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention.</li></ul>

<b>Events <u>Meeting</u> the AE Definition</b>
<ul style="list-style-type: none"><li>• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments (eg, ECG, radiological scans, vital sign measurements), including those that worsen from baseline, considered clinically significant in the medical and scientific judgment of the investigator (ie, not related to progression of underlying disease).</li><li>• Exacerbation of a chronic or intermittent preexisting condition including either an increase in frequency and/or intensity of the condition.</li><li>• New conditions detected or diagnosed after study intervention administration even though it may have been present before the start of the study.</li><li>• Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.</li><li>• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study intervention or a concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an intentional overdose taken with possible suicidal/self-harming intent. Such overdoses should be reported regardless of sequelae.</li></ul>

<b>Events <u>NOT</u> Meeting the AE Definition</b>
<ul style="list-style-type: none"><li>• Any clinically significant abnormal laboratory findings or other abnormal safety assessments which are associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.</li><li>• The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder being studied, unless more severe than expected for the participant's condition.</li></ul>

- Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to the procedure is the AE.
- Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospital).
- Anticipated day-to-day fluctuations of preexisting disease(s) or condition(s) present or detected at the start of the study that do not worsen.

### 10.3.2. Definition of SAE

If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions are met (eg, hospitalization for signs/symptoms of the disease under study, death due to progression of disease).

<b>An SAE is defined as any untoward medical occurrence that, at any dose:</b>	
<b>a. Results in death</b>	
<b>b. Is life-threatening</b>	The term “life-threatening” in the definition of “serious” refers to an event in which the participant was at risk of death at the time of the event. It does not refer to an event that hypothetically might have caused death if it were more severe.
<b>c. Requires inpatient hospitalization or prolongation of existing hospitalization</b>	<p>In general, hospitalization signifies that the participant has been detained (usually involving at least an overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physician’s office or outpatient setting. Complications that occur during hospitalization are AEs. If a complication prolongs hospitalization or fulfills any other serious criteria, the event is serious. When in doubt as to whether “hospitalization” occurred or was necessary, the AE should be considered serious.</p> <p>Hospitalization for elective treatment of a preexisting condition that did not worsen from baseline is not considered an AE.</p>
<b>d. Results in persistent disability/incapacity</b>	<ul style="list-style-type: none"> <li>• The term disability means a substantial disruption of a person’s ability to conduct normal life functions.</li> <li>• This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle) which may interfere with or prevent everyday life functions but do not constitute a substantial disruption.</li> </ul>

**e. Is a congenital anomaly/birth defect**

**f. Other situations:**

- Medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate in other situations such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These events should usually be considered serious.
- Examples of such events include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or development of drug dependency or drug abuse.

**10.3.3. Recording/Reporting and Follow-up of AEs and/or SAEs**

**AE and SAE Recording/Reporting**

The table below summarizes the requirements for recording adverse events on the CRF and for reporting serious adverse events on the Clinical Trial (CT) Serious Adverse Event (SAE) Report Form to Pfizer Safety. These requirements are delineated for 3 types of events: (1) SAEs; (2) nonserious adverse events (AEs); and (3) exposure to the investigational product under study during pregnancy or breastfeeding, and occupational exposure.

It should be noted that the CT SAE Report Form for reporting of SAE information is not the same as the AE page of the CRF. When the same data are collected, the forms must be completed in a consistent manner. AEs should be recorded using concise medical terminology and the same AE term should be used on both the CRF and the CT SAE Report Form for reporting of SAE information.

Safety Event	Recorded on the CRF	Reported on the CT SAE Report Form to Pfizer Safety Within 24 Hours of Awareness
SAE	All	All
Nonserious AE	All	None
Exposure to the investigational product under study during pregnancy or breastfeeding, and occupational exposure	None	All (and exposure during pregnancy [EDP] supplemental form for EDP)

- When an AE/SAE occurs, it is the responsibility of the investigator to review all

<p>documentation (eg, hospital progress notes, laboratory reports, and diagnostic reports) related to the event.</p> <ul style="list-style-type: none"> <li>• The investigator will then record all relevant AE/SAE information in the CRF.</li> <li>• It is <b>not</b> acceptable for the investigator to send photocopies of the participant's medical records to Pfizer Safety in lieu of completion of the CT SAE Report Form/AE/SAE CRF page.</li> <li>• There may be instances when copies of medical records for certain cases are requested by Pfizer Safety. In this case, all participant identifiers, with the exception of the participant number, will be redacted on the copies of the medical records before submission to Pfizer Safety.</li> <li>• The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will be documented as the AE/SAE.</li> </ul>
<p><b>Assessment of Intensity</b></p> <p>The investigator will make an assessment of intensity for each AE and SAE reported during the study and assign it to 1 of the following categories:</p> <ul style="list-style-type: none"> <li>• Mild: An event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities.</li> <li>• Moderate: An event that causes sufficient discomfort and interferes with normal everyday activities.</li> <li>• Severe: An event that prevents normal everyday activities. An AE that is assessed as severe should not be confused with an SAE. Severe is a category utilized for rating the intensity of an event; and both AEs and SAEs can be assessed as severe.</li> </ul> <p>An event is defined as “serious” when it meets at least 1 of the predefined outcomes as described in the definition of an SAE, NOT when it is rated as severe.</p>
<p><b>Assessment of Causality</b></p> <ul style="list-style-type: none"> <li>• The investigator is obligated to assess the relationship between study intervention and each occurrence of each AE/SAE.</li> <li>• A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.</li> <li>• The investigator will use clinical judgment to determine the relationship.</li> <li>• Alternative causes, such as underlying disease(s), concomitant therapy, and other</li> </ul>



risk factors, as well as the temporal relationship of the event to study intervention administration will be considered and investigated.

- The investigator will also consult the investigator's brochure (IB) and/or product information, for marketed products, in his/her assessment.
- For each AE/SAE, the investigator **must** document in the medical notes that he/she has reviewed the AE/SAE and has provided an assessment of causality.
- There may be situations in which an SAE has occurred and the investigator has minimal information to include in the initial report to the sponsor. However, **it is very important that the investigator always make an assessment of causality for every event before the initial transmission of the SAE data to the sponsor.**
- The investigator may change his/her opinion of causality in light of follow-up information and send an SAE follow-up report with the updated causality assessment.
- The causality assessment is one of the criteria used when determining regulatory reporting requirements.
- If the investigator does not know whether or not the investigational product caused the event, then the event will be handled as "related to investigational product" for reporting purposes, as defined by the sponsor. In addition, if the investigator determines that an SAE is associated with study procedures, the investigator must record this causal relationship in the source documents and CRF, and report such an assessment in the dedicated section of the CT SAE Report Form and in accordance with the SAE reporting requirements.

#### Follow-up of AEs and SAEs

- The investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or evaluations as medically indicated or as requested by the sponsor to elucidate the nature and/or causality of the AE or SAE as fully as possible. This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other healthcare professionals.
- If a participant dies during participation in the study or during a recognized follow-up period, the investigator will provide Pfizer Safety with a copy of any postmortem findings including histopathology.
- New or updated information will be recorded in the originally completed CRF.
- The investigator will submit any updated SAE data to the sponsor within 24 hours of receipt of the information.

#### 10.3.4. Reporting of SAEs

##### **SAE Reporting to Pfizer Safety via an Electronic Data Collection Tool**

- The primary mechanism for reporting an SAE to Pfizer Safety will be the electronic data collection tool.
- If the electronic system is unavailable, then the site will use the paper SAE data collection tool (see next section) in order to report the event within 24 hours.
- The site will enter the SAE data into the electronic system as soon as the data become available.
- After the study is completed at a given site, the electronic data collection tool will be taken off-line to prevent the entry of new data or changes to existing data.
- If a site receives a report of a new SAE from a study participant or receives updated data on a previously reported SAE after the electronic data collection tool has been taken off-line, then the site can report this information on a paper SAE form (see next section) or to Pfizer Safety by telephone.

##### **SAE Reporting to Pfizer Safety via CT SAE Report Form**

- Facsimile transmission of the CT SAE Report Form is the preferred method to transmit this information to Pfizer Safety.
- In circumstances when the facsimile is not working, notification by telephone is acceptable with a copy of the CT SAE Report Form sent by overnight mail or courier service.
- Initial notification via telephone does not replace the need for the investigator to complete and sign the CT SAE Report Form pages within the designated reporting time frames.

## **10.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information**

### **10.4.1. Male Participant Reproductive Inclusion Criteria**

Male participants are eligible to participate if they agree to the following requirements during the intervention period and for at least 93 days after the last dose of study intervention, which corresponds to the time needed to eliminate study intervention(s) *plus* an additional 90 days (a spermatogenesis cycle):

- Refrain from donating sperm.

PLUS either:

- Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent;

OR

- Must agree to use contraception/barrier as detailed below:
  - Agree to use a male condom when engaging in any activity that allows for passage of ejaculate to another person.
  - Male participants should be advised of the benefit for a female partner to use a highly effective method of contraception, as a condom may break or leak when having sexual intercourse with a WOCBP who is not currently pregnant.

### **10.4.2. Female Participant Reproductive Inclusion Criteria**

A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies:

- Is not a WOCBP (see definitions below in [Section 10.4.3](#));

OR

- Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), as described below, during the intervention period and for at least 28 days after the last dose of study intervention, which corresponds to the time needed to eliminate any study intervention(s).
- A WOCBP agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.

The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.

#### **10.4.3. Woman of Childbearing Potential (WOCBP)**

A woman is considered fertile following menarche and until becoming postmenopausal unless permanently sterile (see below).

If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot be confirmed before the first dose of study intervention, additional evaluation should be considered.

Women in the following categories are not considered WOCBP:

1. Premenopausal female with 1 of the following:

- Documented hysterectomy;
- Documented bilateral salpingectomy;
- Documented bilateral oophorectomy.

For individuals with permanent infertility due to an alternate medical cause other than the above, (eg, mullerian agenesis, androgen insensitivity), investigator discretion should be applied to determining study entry.

Note: Documentation for any of the above categories can come from the site personnel's review of the participant's medical records, medical examination, or medical history interview. The method of documentation should be recorded in the participant's medical record for the study.

2. Postmenopausal female.

- A postmenopausal state is defined as age 60 years or older or no menses for 12 months without an alternative medical cause.
- A high follicle-stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormone replacement therapy (HRT).
- Females on HRT and whose menopausal status is in doubt will be required to use one of the non-hormonal highly effective contraception methods.

#### **10.4.4. Contraception Methods**

Highly Effective Methods:

1. Intrauterine device (IUD).
2. Bilateral tubal occlusion.

3. Vasectomized partner.
  - Vasectomized partner is a highly effective contraceptive method provided that the partner is the sole sexual partner of the woman of childbearing potential and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used. The spermatogenesis cycle is approximately 90 days.
4. Contraceptive implants.
5. Double-barrier method (any combination of physical and chemical methods).
6. Confirmed infertility of sexual partner.
7. Engaged exclusively in a same-sex relationship.
8. Total abstinence (periodic abstinence is not acceptable).

### **Collection of Pregnancy Information**

For both unapproved/unlicensed products and for marketed products, an exposure during pregnancy (EDP) occurs if:

- A female becomes, or is found to be, pregnant either while receiving or having been exposed (eg, because of treatment or environmental exposure) to the investigational product; or the female becomes or is found to be pregnant after discontinuing and/or being exposed to the investigational product;
- An example of environmental exposure would be a case involving direct contact with a Pfizer product in a pregnant woman (eg, a nurse reports that she is pregnant and has been exposed to chemotherapeutic products).
- A male has been exposed (eg, because of treatment or environmental exposure) to the investigational product prior to or around the time of conception and/or is exposed during his partner's pregnancy.

If a participant or participant's partner becomes or is found to be pregnant during the participant's treatment with the investigational product, the investigator must report this information to Pfizer Safety on the CT SAE Report Form and an EDP supplemental form, regardless of whether an SAE has occurred. In addition, the investigator must submit information regarding environmental exposure to a Pfizer product in a pregnant woman (eg, a participant reports that she is pregnant and has been exposed to a cytotoxic product by inhalation or spillage) to Pfizer Safety using the EDP supplemental form. This must be done irrespective of whether an AE has occurred and within 24 hours of awareness of the

exposure. The information submitted should include the anticipated date of delivery (see below for information related to termination of pregnancy).

Follow-up is conducted to obtain general information on the pregnancy and its outcome for all EDP reports with an unknown outcome. The investigator will follow the pregnancy until completion (or until pregnancy termination) and notify Pfizer Safety of the outcome as a follow-up to the initial EDP supplemental form. In the case of a live birth, the structural integrity of the neonate can be assessed at the time of birth. In the event of a termination, the reason(s) for termination should be specified and, if clinically possible, the structural integrity of the terminated fetus should be assessed by gross visual inspection (unless preprocedure test findings are conclusive for a congenital anomaly and the findings are reported).

If the outcome of the pregnancy meets the criteria for an SAE (ie, ectopic pregnancy, spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomaly [in a live-born baby, a terminated fetus, an intrauterine fetal demise, or a neonatal death]), the investigator should follow the procedures for reporting SAEs.

Additional information about pregnancy outcomes that are reported to Pfizer Safety as SAEs follows:

- Spontaneous abortion includes miscarriage and missed abortion;
- Neonatal deaths that occur within 1 month of birth should be reported, without regard to causality, as SAEs. In addition, infant deaths after 1 month should be reported as SAEs when the investigator assesses the infant death as related or possibly related to exposure to the investigational product.

Additional information regarding the EDP may be requested by the sponsor. Further follow-up of birth outcomes will be handled on a case-by-case basis (eg, follow-up on preterm infants to identify developmental delays). In the case of paternal exposure, the investigator will provide the participant with the Pregnant Partner Release of Information Form to deliver to his partner. The investigator must document in the source documents that the participant was given the Pregnant Partner Release of Information Form to provide to his partner.

## 10.5. Appendix 5: Genetics

### Use/Analysis of DNA

- Genetic variation may impact a participant's response to study intervention, susceptibility to, and severity and progression of disease. Therefore, where local regulations and IRBs/ECs allow, a blood sample will be collected for DNA analysis.
- Genetic research may consist of the analysis of 1 or more candidate genes or the analysis of genetic markers throughout the genome (as appropriate).
- The samples may be analyzed as part of a multistudy assessment of genetic factors involved in the response to study intervention or study interventions of this class to understand treatments for the disease(s) under study or the disease(s) themselves.
- The results of genetic analyses may be reported in the clinical study report (CSR) or in a separate study summary, or may be used for internal decision making without being included in a study report.
- The sponsor will store the DNA samples in a secure storage space with adequate measures to protect confidentiality.
- The samples will be retained as indicated:
  - Samples for banking (see [Section 8.7.2](#)) will be stored indefinitely or other period as per local requirements.
- Participants may withdraw their consent for the storage and/or use of their banked biospecimens at any time by making a request to the investigator; in this case, any remaining material will be destroyed. Data already generated from the samples will be retained to protect the integrity of existing analyses.
- Banked biospecimens will be labeled with a code. The key between the code and the participant's personally identifying information (eg, name, address) will be held at the study site and will not be provided to the sample bank.



## 10.6. Appendix 6: Liver Safety: Suggested Actions and Follow-up Assessments

### Potential Cases of Drug-Induced Liver Injury

Humans exposed to a drug who show no sign of liver injury (as determined by elevations in transaminases) are termed “tolerators,” while those who show transient liver injury, but adapt are termed “adaptors.” In some participants, transaminase elevations are a harbinger of a more serious potential outcome. These participants fail to adapt and therefore are “susceptible” to progressive and serious liver injury, commonly referred to as drug-induced liver injury (DILI). Participants who experience a transaminase elevation above 3 times the upper limit of normal ( $\times$  ULN) should be monitored more frequently to determine if they are an “adaptor” or are “susceptible.”

Liver function tests (LFTs) results should be managed and followed as described below.

In the majority of DILI cases, elevations in aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) precede total bilirubin (TBili) elevations ( $>2 \times$  ULN) by several days or weeks. The increase in TBili typically occurs while AST/ALT is/are still elevated above  $3 \times$  ULN (ie, AST/ALT and TBili values will be elevated within the same laboratory sample). In rare instances, by the time TBili elevations are detected, AST/ALT values might have decreased. This occurrence is still regarded as a potential DILI. Therefore, abnormal elevations in either AST OR ALT in addition to TBili that meet the criteria outlined below are considered potential DILI (assessed per Hy’s law criteria) cases and should always be considered important medical events, even before all other possible causes of liver injury have been excluded.

The threshold of laboratory abnormalities for a potential DILI case depends on the participant’s individual baseline values and underlying conditions. Participants who present with the following laboratory abnormalities should be evaluated further as potential DILI (Hy’s law) cases to definitively determine the etiology of the abnormal laboratory values:

- Participants with AST/ALT and TBili baseline values within the normal range who subsequently present with AST OR ALT values  $>3 \times$  ULN AND a TBili value  $>2 \times$  ULN with no evidence of hemolysis and an alkaline phosphatase value  $<2 \times$  ULN or not available.
- For participants with baseline AST **OR** ALT **OR** TBili values above the ULN, the following threshold values are used in the definition mentioned above, as needed, depending on which values are above the ULN at baseline:
  - Preexisting AST or ALT baseline values above the normal range: AST or ALT values  $>2$  times the baseline values AND  $>3 \times$  ULN; or  $>8 \times$  ULN (whichever is smaller).
  - Preexisting values of TBili above the normal range: TBili level increased from baseline value by an amount of at least  $1 \times$  ULN **or** if the value reaches  $>3 \times$  ULN (whichever is smaller).

Rises in AST/ALT and TBili separated by more than a few weeks should be assessed individually based on clinical judgment; any case where uncertainty remains as to whether it represents a potential Hy's law case should be reviewed with the sponsor.

The participant should return to the investigator site and be evaluated as soon as possible, preferably within 48 hours from awareness of the abnormal results. This evaluation should include laboratory tests, detailed history, and physical assessment.

In addition to repeating measurements of AST and ALT and TBili for suspected cases of Hy's law, additional laboratory tests should include albumin, creatine kinase (CK), direct and indirect bilirubin, gamma-glutamyl transferase (GGT), prothrombin time (PT)/international normalized ratio (INR), total bile acids, and alkaline phosphatase. Consideration should also be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further testing, as needed, for further contemporaneous analyses at the time of the recognized initial abnormalities to determine etiology. A detailed history, including relevant information, such as review of ethanol, acetaminophen (either by itself or as a coformulated product in prescription or over-the-counter medications), recreational drug, supplement (herbal) use and consumption, family history, sexual history, travel history, history of contact with a jaundiced person, surgery, blood transfusion, history of liver or allergic disease, and potential occupational exposure to chemicals, should be collected. Further testing for acute hepatitis A, B, C, D, and E infection and liver imaging (eg, biliary tract) and collection of serum sample for acetaminophen drug and/or protein adduct levels may be warranted.

All cases demonstrated on repeat testing as meeting the laboratory criteria of AST/ALT and TBili elevation defined above should be considered potential DILI (Hy's law) cases if no other reason for the liver function test (LFT) abnormalities has yet been found. **Such potential DILI (Hy's law) cases are to be reported as SAEs, irrespective of availability of all the results of the investigations performed to determine etiology of the LFT abnormalities.**

A potential DILI (Hy's law) case becomes a confirmed case only after all results of reasonable investigations have been received and have excluded an alternative etiology.

## 10.7. Appendix 7: ECG Findings of Potential Clinical Concern

ECG Findings That <u>May</u> Qualify as Adverse Events (AEs)
<ul style="list-style-type: none"> <li>Marked sinus bradycardia (rate &lt;40 bpm) lasting minutes.</li> <li>New PR interval prolongation &gt;280 msec.</li> <li>New prolongation of QTcF to &gt;480 msec (absolute) or by <math>\geq 60</math> msec from baseline.</li> <li>New-onset atrial flutter or fibrillation, with controlled ventricular response rate: ie, rate &lt;120 bpm.</li> <li>New-onset type I second-degree (Wenckebach) atrioventricular (AV) block of &gt;30 seconds' duration.</li> <li>Frequent premature ventricular complexes (PVCs), triplets, or short intervals (&lt;30 seconds) of consecutive ventricular complexes.</li> </ul>
ECG Findings That <u>May</u> Qualify as Serious Adverse Events (SAEs)
<ul style="list-style-type: none"> <li>QTcF prolongation &gt;500 msec.</li> <li>New ST-T changes suggestive of myocardial ischemia.</li> <li>New-onset left bundle branch block (QRS &gt;120 msec).</li> <li>New-onset right bundle branch block (QRS &gt;120 msec).</li> <li>Symptomatic bradycardia.</li> <li>Asystole: <ul style="list-style-type: none"> <li>In awake, symptom-free participants in sinus rhythm, with documented periods of asystole <math>\geq 3.0</math> seconds or any escape rate &lt;40 bpm, or with an escape rhythm that is below the AV node.</li> <li>In awake, symptom-free participants with atrial fibrillation and bradycardia with 1 or more pauses of at least 5 seconds or longer.</li> <li>Atrial flutter or fibrillation, with rapid ventricular response rate: rapid = rate &gt;120 bpm.</li> </ul> </li> <li>Sustained supraventricular tachycardia (rate &gt;120 bpm) ("sustained" = short duration with relevant symptoms or lasting &gt;1 minute).</li> <li>Ventricular rhythms &gt;30 seconds' duration, including idioventricular rhythm (rate &lt;40 bpm), accelerated idioventricular rhythm (<math>40 &lt; x &lt; 100</math>), and</li> </ul>

<p>monomorphic/polymorphic ventricular tachycardia &gt;100 bpm (such as torsades de pointes).</p> <ul style="list-style-type: none"> <li>• Type II second-degree (Mobitz II) AV block.</li> <li>• Complete (third-degree) heart block.</li> </ul>
<p><b>ECG Findings That Qualify as Serious Adverse Events</b></p>
<ul style="list-style-type: none"> <li>• Change in pattern suggestive of new myocardial infarction.</li> <li>• Sustained ventricular tachyarrhythmias (&gt;30 seconds' duration).</li> <li>• Second- or third-degree AV block requiring pacemaker placement.</li> <li>• Asystolic pauses requiring pacemaker placement.</li> <li>• Atrial flutter or fibrillation with rapid ventricular response requiring cardioversion.</li> <li>• Ventricular fibrillation/flutter.</li> <li>• At the discretion of the investigator, any arrhythmia classified as an adverse experience.</li> </ul>
<p>The enumerated list of major events of potential clinical concern are recommended as "alerts" or notifications from the core ECG laboratory to the investigator and Upjohn study team, and not to be considered as all inclusive of what to be reported as AEs/SAEs.</p>

## 10.8. Appendix 8: Clinical Opiate Withdrawal Scale

For each item, circle the number that best describes the patient's signs or symptoms. Rate on just the apparent relationship to opiate withdrawal. For example, if heart rate is increased because the patient was jogging just prior to assessment, the increase pulse rate would not add to the score.


Patient's Name:	Date and Time:
Reason for this assessment:	
<b>Resting Pulse Rate:</b> beats/minute <i>Measured after patient is sitting or lying for one minute</i> 0 pulse rate 80 or below 1 pulse rate 81-100 2 pulse rate 101-120 4 pulse rate greater than 120	<b>GI Upset:</b> <i>over last 1/2 hour</i> 0 no GI symptoms 1 stomach cramps 2 nausea or loose stool 3 vomiting or diarrhea 5 multiple episodes of diarrhea or vomiting
<b>Sweating:</b> <i>over past 1/2 hour not accounted for by room temperature or patient activity.</i> 0 no report of chills or flushing 1 subjective report of chills or flushing 2 flushed or observable moistness on face 3 beads of sweat on brow or face 4 sweat streaming off face	<b>Tremor</b> <i>observation of outstretched hands</i> 0 no tremor 1 tremor can be felt, but not observed 2 slight tremor observable 4 gross tremor or muscle twitching
<b>Restlessness</b> <i>Observation during assessment</i> 0 able to sit still 1 reports difficulty sitting still, but is able to do so 3 frequent shifting or extraneous movements of legs/arms 5 unable to sit still for more than a few seconds	<b>Yawning</b> <i>Observation during assessment</i> 0 no yawning 1 yawning once or twice during assessment 2 yawning three or more times during assessment 4 yawning several times/minute
<b>Pupil size</b> 0 pupils pinned or normal size for room light 1 pupils possibly larger than normal for room light 2 pupils moderately dilated 5 pupils so dilated that only the rim of the iris is visible	<b>Anxiety or Irritability</b> 0 none 1 patient reports increasing irritability or anxiousness 2 patient obviously irritable or anxious 4 patient so irritable or anxious that participation in the assessment is difficult

<p><b>Bone or Joint aches</b> <i>if patient was having pain previously, only the additional component attributed to opiates withdrawal is scored</i></p> <p>0 not present</p> <p>1 mild diffuse discomfort</p> <p>2 patient reports severe diffuse aching of joints/muscles</p> <p>4 patient is rubbing joints or muscles and is unable to sit still because of discomfort</p>	<p><b>Gooseflesh skin</b></p> <p>0 skin is smooth</p> <p>3 piloerection of skin can be felt or hairs standing up on arms</p> <p>5 prominent piloerection</p>
<p><b>Runny nose or tearing</b> <i>Not accounted for by cold-symptoms or allergies</i></p> <p>0 not present</p> <p>1 nasal stuffiness or unusually moist eyes</p> <p>2 nose running or tearing</p> <p>4 nose constantly running or tears streaming down cheeks</p>	<p>Total Score _____</p> <p>The total score is the sum of all 11 items</p> <p>Initials of person completing assessment: _____</p>
<p>Score: 5-12 = mild; 13-24 = moderate; 25-36 = moderately severe; more than 36 = severe withdrawal.</p>	

### 10.9. Appendix 9: VAS Assessment Methods

The overall appearance of all VAS items utilizing the Cambridge Neuropsychological Test Automated Battery (CANTAB) or using comparable software will be similar to the screen images (Figure 2 to Figure 5) shown below. The participants will be trained to use the software at the site.


**Figure 2. Screen Display of Drug Liking VAS**




The questions and anchors on VAS items will be modified appropriately to reflect study specific questions as shown in Figure 3 to Figure 5 (see Table 7).



**Figure 3. Screen Display of High VAS**



**Figure 4. Screen Display of Overall Drug Liking VAS**



**Figure 5. Screen Display of Take Drug Again VAS**



**Table 7. Other Subjective Effects Visual Analog Scales**

SCALE DESCRIPTION	STATEMENT TEXT	RESPONSE ANCHORS
Good Drug Effects	<i>At this moment I can feel good drug effects</i>	0: Not at all 100: Extremely
Bad Drug Effects	<i>At this moment I can feel bad drug effects</i>	
Feeling Sick	<i>At this moment I am feeling sick</i>	
Nausea	<i>At this moment I am feeling nausea</i>	
Any Drug Effects	<i>At this moment I can feel any drug effect</i>	
Sleepy	<i>At this moment I am feeling sleepy</i>	
Dizzy	<i>At this moment I am feeling dizzy</i>	

## **10.10. Appendix 10: Alternative Measures During Public Emergencies**

The alternative study measures described in this section are to be followed during public emergencies, including the COVID-19 pandemic. This appendix applies for the duration of the COVID-19 pandemic globally and will become effective for other public emergencies only upon written notification from Upjohn.

Use of these alternative study measures are expected to cease upon the return of business as usual circumstances (including the lifting of any quarantines and travel bans/advisories).

### **10.10.1. Eligibility**

Not applicable.

### **10.10.2. Telehealth Visits**

Not applicable.

### **10.10.3. Alternative Facilities for Safety Assessments**

Not applicable.

### **10.10.4. Study Intervention**

If the safety of a trial participant is at risk because they cannot complete required evaluations or adhere to critical mitigation steps, then discontinuing that participant from study intervention must be considered.

### **10.10.5. Home Health Visits**

Not applicable.

### **10.10.6. Adverse Events and Serious Adverse Events**

If a participant has COVID-19 during the study, this should be reported as an adverse event (AE) or serious adverse events (SAE) and appropriate medical intervention provided.

It is recommended that the investigator discuss temporary or permanent discontinuation of study intervention with the study medical monitor.

### **10.10.7. Efficacy Assessments**

Not applicable.

### **10.10.8. Independent Oversight Committees**

Not applicable.

### 10.11. Appendix 11: Abbreviations

The following is a list of abbreviations that may be used in the protocol.

Abbreviation	Term
Abs	absolute
ADA	antidrug antibodies
AE	adverse event
ALT	alanine aminotransferase
ANOVA	analysis of covariance
ARCI	addiction research center inventory
AST	aspartate aminotransferase
AUC	area under the curve
AV	atrioventricular
BA	bioavailability
BBB	blood–brain barrier
BBS	Biospecimen Banking System
BE	bioequivalence
β-hCG	beta-human chorionic gonadotropin
BMI	body mass index
BP	blood pressure
bpm	beats per minute
BUN	blood urea nitrogen
CANTAB	Cambridge neuropsychological test automated battery
CFR	Code of Federal Regulations
CIOMS	Council for International Organizations of Medical Sciences
CK	creatine kinase
CL <sub>cr</sub>	creatinine clearance
C <sub>last</sub>	last quantifiable concentration
C <sub>max</sub>	maximum observed concentration
CNS	central nervous system
CO <sub>2</sub>	carbon dioxide (bicarbonate)
CONSORT	Consolidated Standards of Reporting Trials
COW	clinical opiate withdrawal scale
CRF	case report form
CRO	contract research organization
CRU	clinical research unit
CSF	cerebrospinal fluid
CSR	clinical study report
C-SSRS	Columbia-Suicide Severity Rating Scale
CT	clinical trial
CTCAE	Common Terminology Criteria for Adverse Events
CTMS	clinical trial management system
CV	cardiovascular
CYP	cytochrome P450

<b>Abbreviation</b>	<b>Term</b>
DC	discontinuation
DCT	data collection tool
DIA	Drug Administration Instructions
DILI	drug-induced liver injury
DMC	data monitoring committee
DNA	deoxyribonucleic acid
DRE	disease-related event
DU	dispensable unit
EC	ethics committee
ECG	electrocardiogram
eCRF	electronic case report form
E-DMC	external data monitoring committee
EDP	exposure during pregnancy
EDR	extemporaneous dispensing record
EMA	European Medicines Agency
E <sub>max</sub>	maximum effect
EOS	end of study
EU	European Union
ET	early termination
EtCO <sub>2</sub>	end-tidal carbon dioxide
EudraCT	European Clinical Trials Database
FDA	Food and Drug Administration
FIH	first-in-human
FSH	follicle-stimulating hormone
GABA	gamma-amino butyric acid
GCP	Good Clinical Practice
GGT	gamma-glutamyl transferase
HAV IgG	hepatitis A virus immunoglobulin G
HAV IgM	hepatitis A virus immunoglobulin M
HBcAb	hepatitis B core antibody
HBsAg	hepatitis B surface antigen
HCl	hydrochloride
HCVAb	hepatitis C antibody
HIPAA	Health Insurance Portability and Accountability Act
HIV	human immunodeficiency virus
HRT	hormone replacement therapy
IB	investigator's brochure
ICD	informed consent document
ICH	International Council for Harmonisation
ID	identification
IND	investigational new drug application
INR	international normalized ratio
IP manual	investigational product manual

<b>Abbreviation</b>	<b>Term</b>
IR	immediate-release
IRB	institutional review board
IRC	internal review committee
IRT	Interactive Response Technology
IUD	intrauterine device
IUS	intrauterine hormone-releasing system
IV	intravenous
IVRS	Interactive Voice Response System
IWR	interactive Web-based response
$K_{el}$	terminal phase rate constant
LBBB	left bundle branch block
LFT	liver function test
MCH	mean corpuscular hemoglobin
MCHC	mean corpuscular hemoglobin concentration
MCV	mean corpuscular volume
MHP	mental health professional
msec	millisecond
N/A	not applicable
NAb	neutralizing antibodies
NOAEL	no-observed-adverse-effect level
PBMC1	peripheral blood mononuclear cells
PCD	primary completion date
PD	pharmacodynamic(s)
PGx	pharmacogenomic(s)
PI	principal investigator
PIB	powder in bottle
PK	pharmacokinetic(s)
POM	profile of mood states
PR	pulse rate
PT	prothrombin time
PVC	premature ventricular contraction/complex
Q1	first quartile
Q3	third quartile
QTc	corrected QT
QTcB	corrected QT (Bazett's method)
QTcF	corrected QT (Fridericia method)
qual	qualitative
RBC	red blood cell
RNA	ribonucleic acid
RR	respiratory rate
SAE	serious adverse event
SAP	statistical analysis plan
SCr	serum creatinine

Abbreviation	Term
SD	standard deviation
SE	standard error
SoA	schedule of activities
SOP	standard operating procedure
SpO <sub>2</sub>	saturated oxygen
SRSD	single reference safety document
SToD	study team on demand
SUSAR	suspected unexpected serious adverse reaction
T	pregabalin
t <sub>1/2</sub>	terminal elimination half-life
TBili	total bilirubin
THC	tetrahydrocannabinol
UDS	urine drug screen
ULN	upper limit of normal
US	United States
USPI	United States Prescribing Information
VAS	visual analog scale
VT	tidal volume
WBC	white blood cell
WOCBP	woman of childbearing potential



## 10.12. Appendix 12: Summary of Changes

<b>Protocol Title</b>	A phase 4, randomized, double-blind, double-dummy, placebo-and active-controlled, single-dose, six-way crossover study evaluating the abuse potential of Lyrica® taken orally concomitantly with Oxycodone hydrochloride In healthy non-drug dependent, recreational opioid users
<b>Product</b>	Lyrica® (Pregabalin)
<b>Protocol Number</b>	A0081365
<b>Study Type</b>	Phase 4
<b>Amendment</b>	3.0
<b>Protocol Date</b>	17 Nov 2021
<b>Legal/Filing Sponsor</b>	Upjohn US 1 LLC 235 East 42nd Street New York, NY 10017-5703

**Table 8. Summary of changes from Amendment 1.0 dated 12 Nov 2020 to Amendment 2.0 dated 24 Dec 2020**

Section	Old Text (Protocol Amendment 1 dated 12 Nov 2020)	New Text (Protocol Amendment 2 dated 24 Dec 2020)	Rationale for amendment
Administrative Changes <b>Sponsor and Sponsor contacts details updated</b>	Missing  Sponsor name 'Pfizer'	<b>Added</b> Upjohn US 1 LLC [REDACTED] [REDACTED] Global Clinical Strategy [REDACTED] [REDACTED] [REDACTED] Global Clinical Operations [REDACTED] [REDACTED]  The sponsor name changed from 'Pfizer' to 'Upjohn' wherever applicable throughout the protocol	The sponsor for this study is changed from 'Pfizer' to 'Upjohn US 1 LLC'  Administrative changes are made to include updated Sponsor details and a authorized sponsor protocol approvers
<b>Section 2.1 Study Rationale</b> From (4 <sup>th</sup> paragraph):	Pregabalin is a Schedule V controlled substance. Since Lyrica® was approved on 30 December, 2004, the epidemiological studies showed that pregabalin may be used in conjunction with opioids to enhance the 'high' obtained from opioids. <sup>7-9</sup> In addition, observational studies have suggested pregabalin is associated with drug overdose death among individuals with concomitant opioid use. <sup>3,10</sup> A clinical trial (rather than a nonclinical or observational study) is	Pregabalin is a Schedule V controlled substance. Since Lyrica® was approved on 30 December, 2004, the epidemiological studies showed that pregabalin may be used in conjunction with opioids to enhance the 'high' obtained from opioids. <sup>7-9</sup> In addition, observational studies have suggested pregabalin is associated with drug overdose death among individuals with concomitant opioid use. <sup>3,10</sup> A clinical trial (rather than a nonclinical or observational study) is required to evaluate the abuse potential of pregabalin. As a consequence, the FDA requires this post-authorization	The changes were made for clarification (modifying the last sentence from "This clinical trial will evaluate pregabalin in a cross-over design-----" to "As a consequence, the FDA has required this post-authorization safety study (PASS) to evaluate

Section	Old Text (Protocol Amendment 1 dated 12 Nov 2020)	New Text (Protocol Amendment 2 dated 24 Dec 2020)	Rationale for amendment
	required to evaluate the abuse potential of pregabalin. This clinical trial will evaluate pregabalin in a cross-over design with comparison to placebo and a positive control, oxycodone hydrochloride (HCl), regarding abuse-related subjective responses, physiological responses (including an assessment of respiratory depression), and drug pharmacokinetics (PK) in a healthy non-drug dependent population with drug abuse experience.	safety study (PASS) to evaluate pregabalin in a cross-over design with comparison to placebo and a positive control, oxycodone hydrochloride (HCl), regarding abuse-related subjective responses, physiological responses (including an assessment of respiratory depression), and drug pharmacokinetics (PK) in a healthy non-drug dependent population with drug abuse experience.	pregabalin in a cross-over design
<b>Section 5.2 Exclusion Criteria</b>	Participants are heavy smokers (>20 cigarettes per day) and/or use e-cigarettes, pipes, cigars, chewing tobacco, nicotine topical patches, nicotine gum, or nicotine lozenges.	Participants are heavy smokers or users of other types of nicotine products (>20 cigarettes equivalents per day)	Changes are made to provide clarification
<b>Section 5.3.2 Caffeine, Alcohol, and Tobacco</b>	The use of oral or chewed tobacco and/or nicotine-containing products (including topical patches) is not permitted for the entire study	The use of oral or chewed tobacco and/or nicotine-containing products (including topical patches) is not permitted from at least 2 hours before and at least 8 hours after study drug administration.	The changes are made to correct the typographical error
<b>Section 10.1.5 Dissemination of Clinical Study Data</b>	<p>Pfizer fulfills its commitment to publicly disclose clinical study results through posting the results of studies on <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> (ClinicalTrials.gov), the European Clinical Trials Database (EudraCT), and/or <a href="http://www.pfizer.com">www.pfizer.com</a> and other public registries in accordance with applicable local laws/regulations. In addition, Pfizer reports study results outside of the requirements of local laws/regulations pursuant to its standard operating procedures (SOPs).</p> <p><a href="http://www.pfizer.com">www.pfizer.com</a></p> <p>Pfizer posts public disclosure synopses (CSR</p>	<p>Upjohn fulfills its commitment to publicly disclose clinical study results through posting the results of studies on <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> (ClinicalTrials.gov), the European Clinical Trials Database (EudraCT), and other public registries in accordance with applicable local laws/regulations. In addition, Upjohn reports study results outside of the requirements of local laws/regulations pursuant to its standard operating procedures (SOPs).</p> <p>No information added</p>	<p>This is due to change of study sponsor from Pfizer to Upjohn.</p> <p>This information is</p>

Section	Old Text (Protocol Amendment 1 dated 12 Nov 2020)	New Text (Protocol Amendment 2 dated 24 Dec 2020)	Rationale for amendment
	synopses in which any data that could be used to identify individual participants have been removed) on www.pfizer.com for Pfizer-sponsored interventional studies at the same time the US Basic Results document is posted to www.clinicaltrials.gov.		removed due to change of study sponsor from Pfizer to Upjohn
<b>Section 10.1.10 Sponsor's Qualified Medical Personnel</b>	<u>Removed</u> <u>For sites other than a Pfizer CRU, the contact number is not intended for use by the participant directly and if a participant calls that number, he or she will be directed back to the investigator site.</u>	No information added	This statement is removed due to change of study sponsor from Pfizer to Upjohn.

**Table 9. Summary of changes from Amendment 2.0 dated 24 Dec 2020 to Amendment 3.0 dated 17 Nov 2021**

Section	Old Text (Protocol Amendment 2 dated 24 Dec 2020)	New Text (Protocol Amendment 3 dated 17 Nov 2021)	Rationale for amendment
Administrative Changes Sponsor contacts details updated	Global Clinical Strategy [REDACTED]	Clinical Sciences [REDACTED]	Administrative changes to update Sponsor contact details and authorized sponsor protocol approver
<b>Section 10.4.2.</b> (Female Participant Reproductive Inclusion Criteria), bullet #2	Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), with low user dependency, as described below, during the intervention period and for at least 28 days after the last dose of study intervention, which corresponds to the time needed to eliminate any study intervention(s).	Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), as described below, during the intervention period and for at least 28 days after the last dose of study intervention, which corresponds to the time needed to eliminate any study intervention(s).	Change to allow more forms of female contraception
<b>Section 10.4.4.</b> (Contraception Methods)	Highly Effective Methods That Have Low User Dependency: <ol style="list-style-type: none"> <li>1. Intrauterine device (IUD).</li> <li>2. Bilateral tubal occlusion.</li> <li>3. Vasectomized partner. <ul style="list-style-type: none"> <li>• Vasectomized partner is a highly effective contraceptive method provided that the partner is the sole sexual partner of the woman of childbearing potential and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used. The spermatogenesis cycle is approximately 90 days.</li> </ul> </li> </ol>	Highly Effective Methods: <ol style="list-style-type: none"> <li>1. Intrauterine device (IUD).</li> <li>2. Bilateral tubal occlusion.</li> <li>3. Vasectomized partner. <ul style="list-style-type: none"> <li>• Vasectomized partner is a highly effective contraceptive method provided that the partner is the sole sexual partner of the woman of childbearing potential and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used. The spermatogenesis cycle is approximately 90 days.</li> </ul> </li> <li>4. Contraceptive implants.</li> </ol>	Changes to allow more forms of female contraception

Section	Old Text (Protocol Amendment 2 dated 24 Dec 2020)	New Text (Protocol Amendment 3 dated 17 Nov 2021)	Rationale for amendment
		<ul style="list-style-type: none"><li>5. Double-barrier method (any combination of physical and chemical methods).</li><li>6. Confirmed infertility of sexual partner.</li><li>7. Engaged exclusively in a same-sex relationship.</li><li>8. Total abstinence (periodic abstinence is not acceptable).</li></ul>	

## 11. REFERENCES

1. Zaccara G, Gangemi P, Perucca P, et al. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. *Epilepsia* 2011; 52(4):826-36.
2. Garassino MC, Piva S, La Verde N, et al. Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients. *PLoS One* 2013; 8(4):e59981.
3. Abrahamsson T, Berge J, Ojehagen A, et al. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study. *Drug Alcohol Depend* 2017; 174:58-64.
4. Hakkinen M, Vuori E, Kalso E, et al. Profiles of pregabalin and gabapentin abuse by postmortem toxicology. *Forensic Sci Int* 2014; 241:1-6.
5. CSR 720-30015. Abuse Liability of Pregabalin (CI-1008) in Recreational Sedative/Alcohol Users. 09 May 2001.
6. Lyrica® [package insert]. New York, NY: Parke-Davis, Division of Pfizer Inc; 2019.
7. Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. *Drugs* 2017; 77(4):403-26.
8. Dahlman D, Abrahamsson T, Kral AH, et al. Nonmedical Use of Antihistaminergic Anxiolytics and Other Prescription Drugs among Persons with Opioid Dependence. *J Addict* 2016; 2016:9298571.
9. Wilens T, Zulauf C, Ryland D, et al. Prescription medication misuse among opioid dependent patients seeking inpatient detoxification. *Am J Addict* 2015; 24(2):173-7.
10. Gomes T, Greaves S, van den Brink W, et al. Pregabalin and the risk for opioid-related death: a nested case-control study. *Ann Intern Med* 2018; 169(10):732-4.
11. CSR 744-00386. A Single-Dose Food Effect and Relative Bioavailability Study of CI-1008 Capsule and Solution Doses in Healthy Volunteers. 2 Aug 2000.
12. Oxycodone hydrochloride (ROXICODONE®) [Package Insert]. Hazelwood, MO: Mallinckrodt Brand Pharmaceuticals, Inc.
13. Kinnunen M, Piirainen P, Kokki H, et al. Updated clinical pharmacokinetics and pharmacodynamics of oxycodone. *Clin Pharmacokinet* 2019; 58(6):705-25.
14. CSR 744-00578; Evaluation of the Potential Pharmacodynamic Interaction Between Pregabalin and Oxycodone Administered Orally to Healthy Volunteers. 8 Sep 2000.



15. Zacny JP and Gutierrez S. Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers. *Psychopharmacology* 2003; 170:242-54.
16. Setnik B, Roland CL, Pixton G, et al. Measurement of drug liking in abuse potential studies: a comparison of unipolar and bipolar visual analog scales. *J Clin Pharmacol* 2017; 57(2):266-74.
17. Guidance for industry: Abuse-Deterrent Opioids – Evaluation and Labeling. April 2015. Available at: <https://www.fda.gov/files/drugs/published/Abuse-Deterrent-Opioids-Evaluation-and-Labeling.pdf>.